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Diabetic nephropathy (DN) is among the most frequent complications of diabetes and the first 
cause of end-stage renal disease. Despite being successful in animal models, the majority of 
clinical trials for novel drugs targeting DN failed. This lack of translational value may in part be 
due to an inadequate comparability of human disease and animal models that often capture 
only a few aspects of disease. Here we overcome this limitation by developing a multi-
molecular non-invasive humanized readout of DN based on urinary peptidomics. The disease-
modified urinary peptides of two type 2 diabetic (T2D) DN mouse models were identified and 
compared with previously validated urinary peptide markers of DN in humans to generate a 
classifier composed of 21 ortholog peptides. This classifier predicted the response to disease 
and treatment with inhibitors of the renin-angiotensin system (RASi) in mice. The humanized 
classifier was significantly correlated with glomerular lesions. Using a human T2D validation 
cohort consisting of 207 patients, the classifier also distinguished between patients with and 
without DN, and response to RASi. Our approach demonstrates that a combination of multiple 
molecular features similar in both human and animal disease could provide a step change in 
translational drug discovery research in T2D-DN nephropathy.  
 




Diabetic nephropathy (DN) is among the most frequent complications of diabetes 1 and recent 
evidence shows that kidney involvement is the main determinant of the increased risk of death 
in diabetic patients 2. Despite significant advances in the understanding of the molecular 
mechanisms of type 2 diabetic (T2D, accounting for 90-95% of the diabetes cases) DN, the 
current standard-of-care is, however, still based on achieving blood pressure control by use of 
inhibitors of the renin-angiotensin system (RASi) on top of glycemic control. While slowing 
down the progression of DN in most cases, this treatment does not halt the ineluctable 
progression to end stage renal disease (ESRD, 3). Therefore new drugs specifically targeting the 
DN pathophysiology are needed to reduce the burden of this disease. The translation of the 
extensive knowledge and plethora of potential targets 4 obtained in animal models of DN and 
other diseases to the clinic has been extremely limited 3, 4. This has been attributed to the fact 
that: i) human pathophysiology and drug susceptibility are often not adequately captured by 
animal models 5, 6, ii) readouts used in preclinical studies are usually different from the required 
endpoints in clinical trials 7, or, iii) those readouts are based on a single molecule or phenotypic 
trait, not sufficient to assess pathology in detail and identify clinically valuable potential drug 
target (Fig. 1A) 8, 9. Ways have been developed to circumvent these concerns mainly in the field 
of cancer and immunology by the development of humanized mouse models 10. An alternative 
to the development of these humanized animal models, which is technically complicated and 
not always feasible in the context of many complex diseases such as DN, might be the 
optimization of the experimental readout based on a panel of molecular features that are 
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identical in both human and animal disease ignoring the non-human animal disease related 
traits (Fig. 1B).  
While a multitude of animal models of DN exist 11, the most frequently used models of T2D DN 
are the BTBRob/ob mice 12 and uninephrectomized db/db mice on a C57BLKS background 
(UNxdb/db, 11). These two models are obese insulin resistant DN models due to leptin or leptin 
receptor deficiency respectively, displaying renal features similar to that observed in humans, 
including progressive albuminuria with advanced glomerular lesions and mild focal interstitial 
fibrosis. In addition, standard-of-care treatment using RASi confers renoprotection in these 
models 13, 14. However this resemblance to human DN relies on albuminuria and histology, and 
often lacks any established molecular similarity; moreover, access to histological data requires 
animal sacrifice, which is costly, time consuming, and does not allow for longitudinal follow-up.  
In humans, current non-invasive readouts of progression of DN are based on the urinary 
albumin excretion rate (AER) and/or estimation of the glomerular filtration rate (eGFR) using 
serum creatinine. However, reduction of AER is not always correlated with complete reversal of 
all phenotypic and in situ changes observed in preclinical mouse models of DN 13. Moreover, 
while routinely performed in humans, eGFR assessment in mice is of little comparative value, 
because in mice 35-50% of the creatinine is secreted and not attributable to the glomerular 
filtration 15. Although methods for GFR measurement, based on fluorescent inulin clearance, 
have been developed for mice, these are still invasive (and cannot be repeated frequently, 16) 
and will not detect small changes in renal function. 
We and others have shown that urine is a rich and non-invasive source of biomarkers of disease 
in humans 17-19. Mass spectrometry-based analysis of the endogenous urinary peptidome (i.e., 
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not generated by trypsin digestion) allows the assessment of thousands of urinary peptides at 
once. Combined in multi-molecular classifiers of tens to hundreds of peptides, these urinary 
peptides have proven their ability to faithfully describe complex diseases including kidney 
disease 17, 20, cardiovascular disease 21, graft-versus-host disease 22, and cholangiocarcinoma 23. 
A successful example of the use of urinary peptides was the development of a urinary peptide 
based classifier for chronic kidney disease (CKD). Capillary electrophoresis coupled to mass 
spectrometry (CE-MS) was used to study the urinary peptidome of 230 patients compared to 
379 healthy control subjects and led to the identification of a panel of 273 peptides associated 
with advanced CKD 24. These 273 peptides combined into a classifier, termed CKD273, was 
subsequently validated for its capacity to detect CKD in independent cross-sectional studies 
with over 2000 patients including a significant number of patients (~70%) with diabetes 25-28. 
Although initially designed for the detection of CKD, employment of the classifier also allowed 
prediction of progression of CKD in patients with CKD derived from different aetiologies 28, 29, 
including patients with DN 30, 31.  
Based on this knowledge and the available urinary peptide classifiers in human for DN, the aim 
of the current study was to develop the first humanized multimarker readout in animal models 
of DN, using urinary peptidome analysis to improve on the translatability of the results 
obtained in animal models to the clinic for this disease. We showed that this multimarker 
model predicted the response to disease and standard-of-care treatment of DN in mice and in 




The biological parameters, histology and urinary peptidome are highly comparable in 
response to DN and standard-of-care treatment in BTBRob/ob and UNxdb/db mice. 
With the aim to avoid strain- or mutation specific urinary peptide markers and to determine 
whether a generic DN peptidome readout in mice exists, we first analyzed the similarity of 
BTBRob/ob and the UNxdb/db mouse. BTBRob/ob and UNxdb/db mice demonstrated 
hyperglycemia with elevated blood glucose and glycated haemoglobin levels (Table 1) and 
increased body weights (not shown). This was accompanied by renal lesions as shown by the 
increased urinary albumin excretion rate (AER) (Fig. 2A) and glomerular PAS-positive material, 
indicative of glomerulosclerosis (Fig. 2B and C). In both models enalapril, a standard-of-care 
drug inhibiting the renin-angiotensin system (RASi), significantly reduced AER and glomerular 
lesions (Fig. 2A-C), without altering blood glucose or glycosylated haemoglobin levels (Table 1). 
The urinary peptidome of these two mouse strains was analyzed using CE-MS leading to the 
identification of 129 and 158 (Fig. 2D) sequenced peptides with significantly altered urinary 
excretion levels when employing multiple testing in the BTBRob/ob and the UNxdb/db DN 
mouse models compared to non diabetic control mice, respectively (Supplementary Table 1 and 
2). Forty-eight identical peptides were modified with same regulation pattern in both models 
representing 30-37% of the observed peptides with different urinary abundance in DN (Fig. 2E). 
Most of the urinary peptides were collagen fragments (collagen type I alpha-1 and type III 
alpha-1 chains), similar to what has been found in humans with DN and CKD 24, 32. Peptide 
fragments from other proteins, including complement factor D, uromodulin and pro-epidermal 
growth factor were also among the peptides of which the urinary abundance was modified in 
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DN (Supplementary Table 3). Using an approach that we have previously developed for the rat 
33, we identified 64 and 72 similar (orthologs) peptides in the human CKD273 classifier and in 
BTBRob/ob and UNxdb/db mice respectively, showing high molecular similarity between the 
mouse models and human DN. Treatment with RASi modified the urinary secretion of 11 
peptides in BTBRob/ob mice, 18 peptides in the UNxdb/db DN mouse model (Supplementary 
Table 1 and 2). Four of the peptides modified by RASi were identical in both strains (Fig. 2F and 
Supplementary Table 4). Counterintuitive regulation of 2 of these 4 peptides was observed 
after RASi as RASi amplified the DN-induced changes for Napsin-A or SOX-6 fragments. Similar 
observations were reported in the past, where RASi was shown to exacerbate disease-induced 
changes while improving kidney function and histology 34.  
 
Development of a humanized urinary peptide based classifier in T2D nephropathy mice. 
These data indicate that consistent changes were induced both by disease and treatment in 
these different strains. To obtain a generic (eg mutation independent) DN mouse urinary 
peptidome profile, we combined the data from the BTBRob/ob and UNxdb/db mice and their 
respective non-diabetic controls. Individual samples from non-diabetic and diabetic mice of the 
two strains were randomly assigned to a discovery or validation cohort (Table 2). The discovery 
cohort consisted of 10 non-diabetic, 10 DN, and 8 DN mice treated with RASi (Table 2). Ninety-
two sequenced peptides displayed significantly altered urinary excretion levels between DN and 
non-diabetic and/or between treated and untreated DN mice (Supplementary Table 5), 
including 42 out of the 51 overlapping peptides previously identified in the two strains 
separately (Fig. 2E). These 92 peptides were confirmed to be mainly fragments of collagens. We 
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next identified the mouse peptides that could consistently reflect human disease by comparing 
the orthology of mouse urine peptide sequences to that of the 273 peptides in the CKD273-
classifier (Fig. 1B, left panel). Among the 92 peptides significantly associated with DN in the 
mouse, 40 were orthologs (44%, Supplementary Table 5), again supporting high molecular 
similarity between human disease and these preclinical DN mouse models. Using support 
vector machines 24, 21 mouse orthologs that had the best association to DN or RASi treatment 
were combined in a urine peptide classifier (Supplementary Table 6). This 21 peptide classifier 
included four peptides (Supplementary Table 6) which were uniquely changed after RASi and 
were not modified by DN. In this mouse discovery cohort, the humanized peptide classifier was 
able to differentiate between non-diabetic and DN mice (Fig. 3A). The classifier could also 
significantly discriminate between RASi treated and untreated DN mice (Fig. 3A). This 
humanized readout was next tested to validate its accuracy in diagnosing disease and detecting 
drug treatment changes in both an independent cohort of mice and humans.  
 
Validation of the humanized urinary peptide based classifier in an independent set of T2D 
nephropathy mice. 
We further validated the classifier using the additional independent cohort of non-diabetic 
(n=7), untreated DN (n=10) and RASi-treated DN mice (n=10) (Table 2). In this separate 
validation set, significant differences were seen not only between non-diabetic and DN animals, 
but also between untreated DN mice and DN mice treated with RASi (Fig. 3B).  
As the aim of the classifier was prediction of DN and not T2D per se, we assessed the 
association of the humanized classifier with the development of glomerular lesions in the 
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validation cohort. The classifier was highly correlated with glomerular PAS-positive matrix 
accumulation (r=0.6420, p=0.0003, Fig. 3C) and outperformed albuminuria, the standard 
readout, that showed a weaker association with renal lesions (r=0.4839, p=0.0105, Fig. 3D). This 
result supports the hypothesis that multimolecular humanized readouts can better describe 
complex disease phenotypes 9 than individual biomarkers such as albuminuria routinely used as 
a biomarker of DN in man.  
 
Validation of the humanized urinary peptide based classifier in humans.  
Since the CKD273 classifier was based on 273 urine peptides of human origin, we verified that 
the selected reduced subset of mouse ortholog peptides used for the humanized urine peptide 
classifier could efficiently translate to the clinic and predict the presence of DN and respond to 
RASi treatment in humans. Using a discovery cohort of 25 non-diabetic healthy controls and 25 
patients with DN available in the human urinary peptide database 35 (Table 3), we built a 
classifier based on the orthologs, which significantly distinguished between the 2 groups in the 
discovery set (Fig. 4A). For a first independent validation of the classifier we scored a small 
cohort of 42 T2D patients with or without DN, treated either with placebo or with irbesartan, 
an angiotensin II receptor antagonist representing another class of RASi. In this additional 
independent validation cohort, the ortholog-based classifier was able to discriminate T2D 
patients with DN treated with placebo or the RASi (Fig. 4B). As expected, a significant difference 
was also observed between T2D-patients with and without DN (Fig. 4B). We further validated 
the classifier using a previously published cohort 27 of 165 T2D patients among which 87 
displayed DN as defined by macroalbuminuria and/or eGFR <45 mL/min/1.73 m2 27. By this 
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design, macroalbuminuria and eGFR were strongly associated to the presence of DN (AUC of 
0.94 and 0.88 for albuminuria and eGFR, respectively). Patient treatment information was not 
available in this study 27. The humanized classifier clearly separated the 165 T2D-patients with 
and without DN, although with lower sensitivity and specificity than the original CKD273 






The limited success rate of cross-species translation of results from preclinical models to the 
patient still hampers the pharmaceutical development for many complex diseases including DN. 
One major hurdle appears that disease progression and therapeutic effects are not adequately 
captured by animal models 5. Moreover, readouts used in preclinical studies are usually 
different from the required endpoints in clinical trials 7. In animals, the readouts are designed 
to give the highest discriminative power between healthy and diseased animal, e.g., rely on 
tissue examination at termination of the study. In contrast, treatment efficiency assessed in 
clinical trials is often limited to the use of a non- or minimally invasive approach, especially in 
chronic diseases where biomarkers are used to follow disease progression. This limitation can 
be exemplified in the DN area, where phase II studies largely depend on changes in 
albuminuria, which cannot always predict progression of renal lesions or drug treatment 
benefits.   
Here, using urinary peptidomics, we have developed and demonstrated the validity of a non-
invasive, humanized multimarker readout of DN. This classifier was shown to correlate with the 
renal lesions in two prototypic T2D-DN mouse models and also shown to respond to RASi 
treatment in both mouse models and in a cohort of diabetic patients. Therefore, the classifier 
tool defined holds great potential for building the translational bridge between a drug 
candidate’s effects in a mouse DN model to human disease. Although we developed this 
approach for urinary peptides, this concept can, in theory, be applied to any non- or minimal-
invasive biological trait including miRNAs, mRNAs, proteins or metabolites. However the 
availability of reference panels for human disease is a prerequisite.   
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Reliable markers of DN are needed to characterize the severity of disease and to monitor drug 
treatment effects in improving kidney health and function. RASi are drugs routinely used to 
slow-down the progression of DN following the landmark study by Lewis et al. in 1993 36. 
Therefore, we decided to use RASi to validate our strategy that drugs that are effective in 
humans will lead to a positive humanized urinary peptidome readout in selected mouse 
models, and vice versa. We observed that the treatment with RASi (enalapril) moderately, but 
significantly, reduced the score of the humanized urinary peptide classifier, and that reduced 
histopathological lesions accompanied the lower scores. In addition, the classifier score was 
lower in humans with DN treated with irbesartan, an angiotensin II receptor antagonist that 
represents another class of RASi, validating not only the translational value of the classifier, but 
also its sensitivity to different drugs from the same class.  
Our results strengthen the notion that urine is a rich source of biomarkers and support the 
hypothesis that multi-peptide panels/readouts can better describe complex disease phenotypes 
8, 9. This is further exemplified by the observation that this novel humanized urine peptide 
classifier based on 21 urinary peptides displayed a strong and highly significant correlation with 
lesions in-situ, whereas the correlation and significance of albuminuria alone with the score of 
glomerular lesions in mice, routinely used as a biomarker of DN in man, were much lower. 
These results are in accordance with previous observations that albuminuria does not always 
correlates with disease progression in man 37-39, while multimarker urinary peptidome 
classifiers have been suggested to better depict disease progression28, 31, 40. 
The use of body fluid-based humanized classifiers also has the benefit of being non-invasive and 
would permit longitudinal follow-up and on-route adjustment during the drug evaluation 
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process; no animal sacrifice is needed. Furthermore, such non-invasive assessment of 
progression of disease in animals will also more closely mimic the surrogate endpoints in 
human clinical trials where evaluation of renal lesions using kidney biopsies, especially in DN, is 
not routinely performed. In addition, the option to sample multiple times from the same animal 
will significantly reduce the number of animals required for long-term studies.  
Although our model is based upon multiple markers, all markers in the model were derived 
from fragments of either collagen α-1(I) or (III). This can be considered as a limitation as to the 
concept of a multimarker panel to represent multiple disease mechanisms in complex diseases.  
Indeed the collagen-based urinary markers most likely represent the development of fibrosis 41 
that is considered a hallmark of kidney disease 42, 43. When taking into account the non-ortholog 
peptides, some of the corresponding proteins could also be linked to human chronic kidney 
disease or diabetic nephropathy. These include pro-epidermal growth factor 44, uromodulin 45, 
meprin A 46, osteopontin 47, complement factor D 48  and α-1-antitrypsin 49 (Supplementary 
Table 5). Improvement of the applied strategy will come from new sequence information on 
the disease-associated peptides in both mice and humans. Updated orthology models based on 
larger panels of different peptides (i.e. not only composed of collagen I and III fragments) are 
anticipated to be more resistant to variability, provide an optimized description of molecular 
mechanisms of disease and hence to improve the confidence in prediction of disease 
progression and treatment effects. Finally, a validated humanized urine peptide classifier may 
also facilitate decision making about the preclinical model to use for a specific human disease. 
In this context it could add to a recent transcriptomics studies 50 using renal tissue that 
identified cross-species shared transcriptional networks of DN allowing identification of 
14 
 
pathways unique to each of the human-mouse strain networks. Such approaches could reduce 
the number of different animal models currently used for drug discovery today.  
In conclusion we have developed, based on a new concept, the first humanized non-invasive 
multi-peptide classifier that could provide a step change in translational drug discovery 
research in T2D-DN.   
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RESEARCH DESIGN AND METHODS  
Animals and experimental design  
Male diabetic db/db mice (BKS.Cg-Dock7m +/+ Leprdb/J stock no. 000642) and female 
BTBRob/ob mice (BTBR.V(B6)-Lepob/WiscJ stock no. 004824) and their respective lean 
littermates db/m and BTBR were purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA). All mice had free access to food and water and were maintained on a 12-h light/dark 
cycle at 21-22°C. Db/m and db/db mice were subjected to right side uninephrectomy (UNx) 
under anesthesia at 8 weeks of age to accelerate development of diabetic nephropathy as 
described previously 51. The following groups of mice were studied: (i) untreated BTBRob/ob 
diabetic mice (n=9); (ii) BTBRob/ob diabetic mice treated with enalapril (Sigma E6888-5G) 
admixtured in drinking water 200 mg/l with a non-caloric sweetener (Splenda, 240mg/l) for 12 
weeks from age 8 to 20 weeks (n=9); (iii) untreated BTBR non-diabetic lean mice (n=9); (iv) 
untreated UNxdb/db diabetic mice (n=11); (v) UNxdb/db diabetic mice treated with enalapril 
for 4 weeks from age 18 to 22 weeks (n=9); (vi) untreated UNxdb/m non-diabetic lean mice 
(n=8). Mice were sacrificed under isoflurane anesthesia at 20 weeks of age in BTBRob/ob and at 
22 weeks of age in UNxdb/db. Kidneys were collected for histologic analyses. The experimental 
protocols were approved by the Animal Care Committee at the University of Utah (UNxdb/db) 
and the Local Ethics Review Committee on Animal Experiments in the Göteborg Region 
(BTBRob/ob). 
 
Blood and urine chemistry 
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Blood glucose and HbA1c levels were measured in fasted awake mice using an Accu-Chek 
(Roche, REF 05599415370; BTBRob/ob) or a glucose meter (Glucometer Elite XL, Bayer 
Healthcare, Elkhart, IN, USA; UNxdb/db) and HbA1cNow+ (Bayer, REF 81611409-3038; 
BTBRob/ob) or DC 2000+ HbA1C kit (Bayer Healthcare; UNxdb/db). To determine albumin 
excretion rates (AER, μg/24 h) urine was collected from metabolic cages. During urine collection 
mice had free access to food and water. Urine albumin concentration was measured using a 
mouse specific albumin ELISA (ICL, E-90AL; BTBRob/ob) or a laser nephelometer (Hyland, 
Deerfield, Illinois; UNxdb/db) using a monospecific antibody to rat serum albumin (Cappel 
Laboratories, West Chester, Pennsylvania).  
 
Histological analysis 
Kidneys were fixed in Carnoy solution, dehydrated in alcohol, and embedded in paraffin. Two-
micrometer sections were stained with periodic acid-Schiff reagent. At least 50 glomeruli, 
including superficial and juxtaglomerullary cortical area, were examined for each animal. The 
extent of glomerular damage was expressed as the percentage of glomerular area fraction 
occupied by PAS-positive matrix 51. 
  
Urine peptidomics 
Sample preparation: Thirteen hour-urine obtained from BTBRob/ob mice at 20 weeks age and 
bladder urine collected from UNxdb/db mice at 22 weeks age at termination were used for 
peptide profiling, respectively. One hundred fifty µl of mouse urine sample was diluted with the 
same volume of a solution composed of 2 M urea, 10 mM NH4OH and 0.2% SDS. Subsequently, 
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samples were ultrafiltered using a Centristat 20 kDa cut-off centrifugal filter device (Satorius, 
Göttingen, Germany) to eliminate high molecular weight molecules. The filtrate was desalted 
using a NAP5 gel filtration column (GE Healthcare Bio Sciences, Uppsala, Sweden) to remove 
urea and electrolytes, and thereby to decrease matrix effects. The sample was lyophilized in a 
Savant speedvac SVC100H connected to a Virtis 3L Sentry freeze dryer (Fischer Scientific, 
Illkirch, France) and stored at 4°C until use. Shortly before CE-MS analysis, the samples were re-
suspended in 10µL HPLC grade H2O.  
CE-MS Analysis: CE-MS analysis was performed as previously described 52, 53. Briefly, CE-MS 
analyses were performed using a Beckman Coulter Proteome Lab PA800 capillary 
electrophoresis system (Beckman Coulter, Fullerton, USA) on-line coupled to a micrOTOF II MS 
(Bruker Daltonic, Bremen, Germany). The electro-ionization sprayer (Agilent Technologies, Palo 
Alto, CA, USA) was grounded, and the ion spray interface potential was set to –4.5 kV. Data 
acquisition and MS acquisition methods were automatically controlled by the CE via contact-
close-relays. Spectra were accumulated every 3 s, over a range of m/z 350 to 3000.  
Data Processing and Cluster Analysis: MosaiquesVisu software package was applied to 
deconvolve mass spectral ion peaks representing identical molecules at different charge states 
into single masses 54. Migration time and ion signal intensity (amplitude) were normalized using 
internal polypeptide standards 55. Each polypeptide present in the list was defined by its 
normalized migration time [min], molecular mass [kDa], and signal intensity detected. Using a 
Microsoft SQL database, all detected polypeptides were deposited, matched, and annotated in 
order to allow for further comparison between the groups. The criteria applied to considered a 
polypeptide identical was that within different samples the mass deviation was lower than 50 
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ppm for masses <4kDa, 150 ppm for masses >6kDa, and between 50-150 ppm for masses 
between 4-6kDa. Acceptable migration time deviation was between 1 and 2.5 minutes. 
Peptide sequencing: For sequencing, processed urine samples were also separated on a Dionex 
Ultimate 3000 RSLS nano flow system (Dionex, Camberly UK). A 5 µl sample was loaded onto a 
Dionex 5 mm C18 nano trap column at a flowrate of 5 µl/min. Elution was performed on an 
Acclaim PepMap 75 mm C18 nano column over 100 min. The sample was ionised in positive ion 
mode using a Proxeon nano spray ESI source (Thermo Fisher Hemel UK) and analyzed in an 
Orbitrap Velos FTMS (Thermo Finnigan, Bremen, Germany). The MS was operated in data-
dependent mode to switch between MS and MS/MS acquisition and parent ions were 
fragmented by (high-) energy collision-induced dissociation and also electron transfer 
dissociation. Data files were searched against Mus musculus entries in the Swiss-Prot database 
without any enzyme specificity using Open Mass Spectrometry Search Algorithm (OMSSA, 
http://pubchem.ncbi.nlm.nih.gov/omssa) with an e-value cut-off of 0.1. No fixed modification 
and oxidation of methionine as variable modifications were selected. Mass error windows of 10 
ppm for MS and 0.05 Da (HCD) or 0.5 Da (CID, ETD) for MS/MS were allowed. For further 
validation of obtained peptide identifications, the strict correlation between peptide charge at 
pH 2 and CE-migration time was utilized to minimize false-positive identification rates 56. 
Calculated CE-migration time of the sequence candidate based on its peptide sequence 
(number of basic amino acids) was compared to the experimental migration time. Peptides 
were accepted only if they had a mass deviation below ± 80 ppm and a CE-migration time 





Human data CE-MS and patient data 
Human CE-MS data and general patient characteristics (Table 5) were extracted from the 
human urinary peptide database 35 and from 27. The study was designed and conducted fulfilling 
all of the requisites of the laws on the protection of individuals collaborating in medical 
research and was in accordance with the principles of the Declaration of Helsinki. All datasets 
included in the study derived from previous studies and all data were anonymized. The 
approach employing anonymized proteomics data from previous studies was approved by the 
local ethics committee. 
 
Orthology 
To examine the orthology between mouse peptides and human peptides from CKD273 24 we 
applied three criteria: first, we looked for identical fragments; secondly, we looked for 
fragments with one identical cleavage site (N or C-term) and third, we looked for peptides from 
the same protein area with a minimum overlap in 6 amino acids. 
 
Statistics 
Comparisons and correlations: Statistical comparisons between two groups were assessed using 
a Mann-Whitney test for independent samples. Correlations were assessed using a non-




Biomarker selection and classifier modelling: For the identification of potential biomarkers, the 
reported p-values were calculated using the Wilcoxon Rank-Sum test (R-based statistic 
software, version 2.15.3) followed by adjustment for multiple testing using the method 
described by Benjamini and Hochberg 57. Peptides that were detectable in >70% of mice in at 
least one group and reached an adjusted p-value of <0.05 were further considered as relevant. 
Using MosaCluster software package 52 we next used a support vector machine (SVM)-based 
approach 58 to generate a prognostic biomarker classifier based on 21 mice ortholog 
biomarkers associated with DN and that were sequenced. The parameters of the kernel 
function for the 21-dimensional hyperplane were: penalty parameter (C) of 4 and kernel width 
(γ) of 0.00819. The ortholog-based human model was formed by 19 biomarkers and the 
parameters used for the hyperplane were: penalty parameter (C) of 1024 and kernel width (γ) 
of 0.00012. Sensitivity and specificity were calculated based on the number of properly 
classified samples. The overall yield of the polypeptide pattern was evaluated by the receiver 
operating characteristic (ROC) and area under curve (AUC) plots with MedCalc software 
(MedCalc version 8.1.1.0, MedCalc Software, Belgium).  
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Fig. 1. Improving the translatability of animal models of disease by the development of a 
multimolecular humanized readout. A: Disease readouts are often based on a single phenotypic 
trait or biomarker similar, if possible, in animals and humans. Such single feature does not 
capture the complexity of most disorders. Hence novel drugs, although successful in the 
preclinical phase based on such single feature readout in animal models, often fail in humans. 
B: In contrast, the analysis of multimolecular changes using omics approaches, by for example 
urinary peptidomics, allows a more complete description of complex phenotypes. Furthermore 
the combination of these multiple features similar (ortholog) in human disease and animal 
models, leading to a “humanized” readout, most likely will more efficiently translate the effects 
of new drugs in preclinical models to the clinic. 
 
Fig. 2. The biological response, histology and urinary peptidome are highly comparable in two 
frequently used T2D nephropathy mouse strains. A: albumin excretion rate, B: glomerular 
periodic acid Schiff staining -positive matrix fraction and C: representative histology sections of 
glomerular mesangial matrix deposition stained with periodic acid Schiff staining; Scale bars: 
100μm. D: Representation of urinary peptides significantly modified between non-diabetic and 
mice with DN. Each peptide is identified using CE-MS by a unique identifier on the basis of the 
migration time (min) and specific mass (kDa), with a peak height representing the relative 
abundance. E and F: Venn diagrams showing the overlap of urinary peptides significantly 
modified in the two T2D mouse strains with DN and overlap in response to RASi. BTBRob/ob, 
T2D mice with leptin-deficiency mutation; Unxdb/db uninephrectomized T2D mice with a 
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mutation in the leptin receptor; No diab, lean control mice; DN, T2D mice with diabetic 
nephropathy; DN+RASi, T2D mice with diabetic nephropathy treated with inhibitors of the renin 
angiotensin system (RASi, enalapril); PAS+, periodic acid Schiff positive; AER, urinary albumin 
excretion rate. *p<0.05 versus No diab. °p<0.05 versus non treated DN. Mann-Whitney test for 
independent samples. Data presented as mean ± SEM. 
 
Fig. 3. Development and validation of a humanized urinary peptide based classifier in T2D 
nephropathy mice. A: scores of the humanized classifier in the discovery cohort consisting of 10 
non-diabetic, 10 untreated diabetic and 8 diabetic mice treated with RASi and in the validation 
cohort B: consisting of 7 non-diabetic, 10 untreated diabetic and 10 RASi-treated diabetic mice. 
C-D: Correlation of the humanized urine peptide classifier score (C) and albumin excretion rate 
(D) with the glomerular mesangial matrix deposition assessed by periodic acid Schiff staining 
using the Spearman correlation test. No. diab, lean control mice; DN, T2D mice with diabetic 
nephropathy; RASi: enalapril; PAS+, periodic acid Schiff positive; AER, urinary albumin excretion 
rate; BTBRob/ob, type 2 diabetic mice; UNxdb/db mice, type 2 diabetic mice. *p<0.05 versus No 
diab. °p<0.05 versus DN. Mann-Whitney test for independent samples. Data presented as mean 
± SEM.  
 
Fig. 4. Validation of the humanized urinary peptide based classifier in humans. A: Scores of the 
humanized urine peptide classifier in a discovery human cohort consisting of 25 healthy 
controls and 25 patients with T2D and DN. B: Scores of the humanized urine peptide classifier in 
a validation cohort consisting of 14 patients with T2D without DN, 14 patients with DN treated 
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with placebo and 14 patients with DN treated with RASi. C: Score, AUC, sensitivity and 
specificity of the humanized urine peptide classifier and the CKD273 classifier in a 
supplementary human cohort consisting of 165 T2D-patients with (n=87) and without DN 
(n=78), for patient details see 27. No. diab, healthy humans; DN, diabetic humans with diabetic 
nephropathy; Diab. noDN, diabetic humans without diabetic nephropathy; RASi: irbesartan;  
Pla, placebo; AUC, area under the curve. *p<0.05 versus No diab. or Diab. noDN. °p<0.05 versus 




Table 1. Blood chemistry data of BTBRob/ob and UNxdb/db mice.  
 
 BTBR Unxdb 
  No diab. (BTBR) DN (BTBRob/ob) DN+RASi No diab. (Unxdb/m) DN (Unxdb/db) DN+RASi 
Glucose (mM) 9.1 ±0.2 24.3 ±2,8* 26.3 ±2.9* 5.7 ±0.5  33.3 ±4.7* 33.3 ±0.0* 
HbA1c (%)[mmol/mol] 4.7 ±0.1 [28 ±1] 11.5 ±0.4 [103 ±4]* 11.5 ±0.4 [102 ±4]* 4.0 ±0.1 [20 ±1] 13.3 ±0.4 [123 ±4]* 13.4 ±0.4 [123 ±5]* 
Data presented as mean ± SEM (n=5-11/ group). BTBRob/ob, T2D mice with leptin-deficiency mutation; Unxdb/db uninephrectomized T2D mice 
with a mutation in the leptin receptor; No diab., lean control mice; DN, T2D mice with diabetic nephropathy; DN+RASi, T2D mice with diabetic 
nephropathy treated with inhibitors of the renin angiotensin system (RASi, enalapril); HbA1c, glycated haemoglobin A1c. *p<0.05 versus No 
diab. Mann-Whitney test for independent samples. 
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Table 2. Biochemistry data of mouse discovery and validation cohorts. 
 
 Discovery cohort Validation cohort 
  No diab. DN DN+RASi No diab. DN DN+RASi 
Number (BTBRob/ob/Unxdb/db) 10 (5/5) 10 (5/5) 8 (4/4) 7 (4/3) 10 (4/6) 10 (5/5) 
Albumin excretion rate (mg/24h) 0.03 ±0.01 1.4 ±0.4* 0.4 ±0.11*,° 0.1 ±0.1 1.1 ±0.3* 0.7 ±0.3* 
Glomerular PAS+ (%) 19.6 ±4.0 50.1 ±2.5* 25.5 ±1.4° 14.1 ±1.1 44.5 ±1.2* 32.5 ±3.6*,° 
Blood glucose (mM) 7.2 ±0.7 25.6 ±3.2* 27.3 ±3.0* 7.8 ±0.8 30.6 ±2.1* 31.8 ±1.6* 
HbA1c (%)[mmol/mol] 4.4 ±0.1 [24 ±1] 11.8 ±0.5 [105 ±6]* 12.3 ±0.6 [111 ±7]* 4.5 ±0.2 [25 ±2] 12.8 ±0.4 [117 ±4]* 12.5 ±0.5 [114 ±5]* 
 Data presented as mean ± SEM. No diab., lean control mice; DN, T2D mice with diabetic nephropathy; RASi: enalapril; AER, urinary albumin 
excretion rate; PAS+, periodic acid Schiff positive; HbA1c, glycated haemoglobin A1c; BTBRob/ob, type 2 diabetic mice; UNxdb/db mice, type 2 
diabetic mice. *p<0.05 versus No diab. °p<0.05 versus DN. Mann-Whitney test for independent samples.  
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Table 3. Biochemistry data of human discovery and validation cohorts. 
 
Data presented as mean ± SEM. No diab., healthy humans; DN, diabetic humans with diabetic nephropathy; Diab. noDN, diabetic humans 
without diabetic nephropathy; RASi: irbesartan;  Pla, placebo; n.a, not available; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin A1c; U-albumin or U-protein, urinary albumin or urinary protein excretion, respectively. Since data were collected from different 
cohorts, urinary albumin was measured using different collection-and normalisation-methods. For 5 patients U-albumin or protein was not 
available. *p<0.05 versus No diab. or Diab. noDN. °p<0.05 versus DN+Pla. Mann-Whitney test for independent samples. 
 Discovery cohort Validation cohort Supplementary cohort 
  No diab. DN Diab. noDN DN+Placebo DN+RASi Diab. noDN DN 
Gender (M/F) 20/5 25/0 11/3 14/0 12/2 19/28 (for 31 n.a.) 35/23 (for 29 n.a.) 
Age (years) 62.4 ±4.0 65.1 ± 5.5 63.9 ± 4.7 67.3 ± 4.7 65.4 ± 4.6 58.1 ± 14.2 (for 33 n.a) 62.6 ± 14.7 (for 28 n.a.) 
eGFR (mL/min/1.73m2) 75.3 ±7.5 55.5 ± 4.6* 80.1 ± 5.4 53.1 ± 3.1* 53.9 ± 4.8* 90.1 ± 19.0 47.6 ± 27.6* 
HbA1c (%)[mmol/mol] n.a. 6.5 ± 0.7 [48 ±2] 7.8 ± 0.9 [63 ±3] 7.2 ± 0.8 [55 ±2] 8.5 ± 0.6 [69 ±2]° n.a. n.a. 
U-Albumin          
mg/mL 2.3 ± 5.3 228.2 ± 241.6 * 41.1 ± 27.7 71.6 ± 76,3   11.8 ± 7.2 (n=28) 994.4 ± 2224.5 (n=32) 
mg/g creatinine        6.3 ± 5.8 (n=31) 655.4 ± 714.3 (n=30) 
mg/24h      241.0 ± 282.3 7.4 ± 5.7 (n=19) 3682.5 ± 2999.3 (n=10) 
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AUC [CI 95%] 0.729 [0.654-0.795] 0.948 [0.902-0.977]
Sensitivity [CI 95%] (%) 81 [76-92] 90 [81-95]
Specificity [CI 95%] (%) 59 [47-76] 92 [84-97]
Peptide_ID Sequence Protein name Start Stop Uniprot Masse CE-Time Adjusted pValue Freq BTBR  mean Amp. BTBR
Freq 
BTBRob/ob




















710 SpGRDGApG Collagen	  alpha-­‐1(I)	  chain 1012 1020 P11087 844,43 33,46 0,01840412 1 247,45 0,33 68,87 0,278318852 down-­‐regulated	  in	  ob/ob
1127 ApGERGPpG Collagen	  alpha-­‐1(III)	  chain 678 686 P08121 868,45 33,7 0,004385248 1 307,74 0,22 20,91 0,067946968 down-­‐regulated	  in	  ob/ob
2465 QVSPGAKmP Transcription	  factor	  SOX-­‐6 378 386 P40645 929,47 35,74 0,02548084 0,11 9,45 0,89 1230,7 130,2328042 up-­‐regulated	  in	  ACEi
2756 GPpGENGKpG Collagen	  alpha-­‐1(III)	  chain 647 656 P08121 940,48 34,25 0,012142689 0,78 103,41 0,11 2,62 0,025336041 down-­‐regulated	  in	  ob/ob
2806 YRELVHQ Alpha-­‐1-­‐antitrypsin	  1-­‐1 56 62 P07758 943,5 28,34 0,049524642 0,78 72,76 0,11 74,71 1,02680044 up-­‐regulated	  in	  ob/ob
3062 GQpGEKGPpG Collagen	  alpha-­‐1(III)	  chain 926 935 P08121 954,47 34,61 0,007164724 0,89 165,18 0,22 11,39 0,068955079 down-­‐regulated	  in	  ob/ob 0,01921313 0,22 11,39 1 1327,35 116,5364355 up-­‐regulated	  in	  ACEi reversed	  by	  ACEi	  treatment
3144 GPpGESGREG Collagen	  alpha-­‐1(I)	  chain 996 1005 P11087 957,46 34,3 0,003740306 1 82,52 0 0 0 down-­‐regulated	  in	  ob/ob
3268 FVNNDLKL Alpha-­‐1-­‐antitrypsin	  1-­‐1 137 144 P07758 961,5 34,74 0,00717354 1 556,21 0,78 275,02 0,494453534 down-­‐regulated	  in	  ob/ob 0,03642468 0,78 275,02 0 0 0 down-­‐regulated	  in	  ACEi
3438 DGKTGPpGPAG Collagen	  alpha-­‐1(I)	  chain 539 549 P11087 968,51 37,23 0,004385248 1 434,59 0,33 23,6 0,054304057 down-­‐regulated	  in	  ob/ob
3736 VLNLGPITR Uromodulin 599 607 Q91X17 981,62 35,78 0,014035669 0,89 428,51 0,11 68,63 0,160159623 down-­‐regulated	  in	  ob/ob
4385 GPpGERGGpGP Collagen	  alpha-­‐1(III)	  chain 503 513 P08121 1008,51 35,45 0,004385248 1 698,93 0,56 113,81 0,162834619 down-­‐regulated	  in	  ob/ob
4520 ASLQPETLR Serine	  protease	  inhibitor	  A3K 288 296 P07759 1013,55 38,53 0,004385248 0,89 502,01 0 0 0 down-­‐regulated	  in	  ob/ob
4856 ApGEKGEGGpP Collagen	  alpha-­‐1(III)	  chain 828 838 P08121 1026,53 36,03 0,020852404 0,89 162,82 0,11 40,59 0,249293699 down-­‐regulated	  in	  ob/ob
4882 GQPGAKGEpGD Collagen	  alpha-­‐1(I)	  chain 810 820 P11087 1027,51 36,35 0,017010274 0,22 23,65 0,78 452,11 19,1167019 up-­‐regulated	  in	  ob/ob
5204 SpGPDGKTGPp Collagen	  alpha-­‐1(I)	  chain 535 545 P11087 1040,53 36,08 0,009919353 1 1273,46 0,78 365,04 0,286652113 down-­‐regulated	  in	  ob/ob
5229 SpGAKGEVGPAG Collagen	  alpha-­‐1(III)	  chain 345 356 P08121 1041,49 37,04 0,003740306 1 178,89 0 0 0 down-­‐regulated	  in	  ob/ob
5599 ApGKDGPpGPAG Collagen	  alpha-­‐1(III)	  chain 897 908 P08121 1051,54 36,38 0,01921313 1 1147,13 0 0 0 down-­‐regulated	  in	  ACEi
5677 ApGDRGEAGPp Collagen	  alpha-­‐1(I)	  chain 787 797 P11087 1054,52 36,74 0,002949087 1 934,56 0,89 332,3 0,355568396 down-­‐regulated	  in	  ob/ob 0,03777412 0,89 332,3 0,33 17,36 0,05224195 down-­‐regulated	  in	  ACEi
5807 SpGGKGEMGPAG Collagen	  alpha-­‐1(III)	  chain 390 401 P08121 1059,5 37,01 0,005095706 1 800,29 0,89 358,58 0,448062577 down-­‐regulated	  in	  ob/ob
5886 GPpGPTGPTGPp Collagen	  alpha-­‐1(I)	  chain 321 332 P11087 1062,53 47,72 0,005037542 1 558,21 0,44 38,15 0,068343455 down-­‐regulated	  in	  ob/ob
6895 RpGEVGPpGPp Collagen	  alpha-­‐1(I)	  chain 907 917 P11087 1106,59 35,07 0,004385248 0,89 168,93 0 0 0 down-­‐regulated	  in	  ob/ob
6927 KPGppGEpGPQ Collagen	  alpha-­‐1(VIII)	  chain 289 299 Q00780 1107,57 38,4 0,005095706 1 640,91 0,78 229,8 0,358552683 down-­‐regulated	  in	  ob/ob
6997 SISGEYNLKT Alpha-­‐1-­‐antitrypsin	  1-­‐1 310 319 P07758 1110,58 36,36 0,00768409 0,89 401,38 0,33 68,79 0,171383726 down-­‐regulated	  in	  ob/ob
7020 DQTRVLNLGP Uromodulin 595 604 Q91X17 1111,62 36,1 0,00768409 0,78 265,87 1 1753,49 6,595290932 up-­‐regulated	  in	  ob/ob
7064 GpPGSpGSpGEQ Collagen	  alpha-­‐1(I)	  chain 1107 1118 P11087 1113,49 47,49 0,004344693 1 427,02 0,11 6,82 0,015971149 down-­‐regulated	  in	  ob/ob
7194 GPpGPTGPTGPpG Collagen	  alpha-­‐1(I)	  chain 321 333 P11087 1119,54 47,64 0,014205913 0,89 521,69 0,33 60,8 0,116544308 down-­‐regulated	  in	  ob/ob
7213 GpGERGEHGPp Collagen	  alpha-­‐1(III)	  chain 795 805 P08121 1120,55 28,62 0,023549868 1 553,03 0,44 192,41 0,347919643 down-­‐regulated	  in	  ob/ob
7284 GGKGEQGPAGpPG Collagen	  alpha-­‐2(I)	  chain 547 559 Q01149 1123,55 36,25 0,041310707 1 332,29 0,44 109,65 0,329982846 down-­‐regulated	  in	  ob/ob
7366 FLEQIHVLE Major	  urinary	  protein	  1 59 67 P11588 1126,63 38,99 0,004385248 1 598,37 0,22 27,34 0,045690793 down-­‐regulated	  in	  ob/ob
7489 VSINKELQNS Kidney	  androgen-­‐regulated	  protein 25 34 P61110 1130,63 36,82 0,012142689 0,78 1181,69 0,11 5,28 0,004468177 down-­‐regulated	  in	  ob/ob
7700 SpGKAGEDGHpG Collagen	  alpha-­‐2(I)	  chain 143 154 Q01149 1139,55 29,02 0,004385248 1 1987,99 0,89 922,37 0,463971147 down-­‐regulated	  in	  ob/ob
7719 GLpGAAGERGPSG Collagen	  alpha-­‐1(III)	  chain 476 488 P08121 1140,56 38,23 0,00768409 1 469,88 0,78 178,78 0,380480123 down-­‐regulated	  in	  ob/ob
7786 GPpGPLGpPGLPG Collagen	  alpha-­‐1(XI)	  chain 1427 1439 Q61245 1143,56 47,71 0,002949087 1 5555,04 1 1332,1 0,239800253 down-­‐regulated	  in	  ob/ob
7814 DGApGAKGDRGE Collagen	  alpha-­‐1(I)	  chain 1016 1027 P11087 1144,57 31,02 0,031121543 1 586,1 1 383,27 0,653932776 down-­‐regulated	  in	  ob/ob
8166 GPpGPpGPpGPPS Collagen	  alpha-­‐1(I)	  chain 1170 1182 P11087 1157,54 47,77 0,009799137 0,89 1090,03 0,44 132,24 0,121317762 down-­‐regulated	  in	  ob/ob
8240 SpGPAGPRGPVGP Collagen	  alpha-­‐1(III)	  chain 1131 1143 P08121 1160,59 37,28 0,042327425 0,33 30,79 0,78 219,78 7,138031829 up-­‐regulated	  in	  ob/ob 0,02744468 0,78 219,78 1 877,1 3,990808991 up-­‐regulated	  in	  ACEi
8738 ApGEKGEGGPpGP Collagen	  alpha-­‐1(III)	  chain 828 840 P08121 1180,58 37,84 0,012479191 1 1637,58 1 807,95 0,493380476 down-­‐regulated	  in	  ob/ob
9077 SpGPDGKTGPpGP Collagen	  alpha-­‐1(I)	  chain 535 547 P11087 1194,61 37,73 0,048043989 1 4026,93 1 2969,04 0,737296154 down-­‐regulated	  in	  ob/ob
9139 SpGQRGEpGPQG Collagen	  alpha-­‐1(III)	  chain 363 374 P08121 1197,58 37,06 0,014018563 0,89 1383,69 0,78 761,42 0,550282216 down-­‐regulated	  in	  ob/ob
9415 VGPRVGLARAQS Napsin-­‐A 387 398 O09043 1209,74 30,12 0,004385248 1 2059,96 0,22 18,38 0,008922503 down-­‐regulated	  in	  ob/ob
9460 DGKTGPpGPAGQD Collagen	  alpha-­‐1(I)	  chain 539 551 P11087 1211,61 39,95 0,012142689 0,78 228,89 0,11 7,7 0,033640613 down-­‐regulated	  in	  ob/ob
9523 GPpGESGREGSpG Collagen	  alpha-­‐1(I)	  chain 996 1008 P11087 1214,56 37,26 0,004385248 1 2120,9 1 1384,76 0,6529115 down-­‐regulated	  in	  ob/ob
9525 GPpGPpGPpGPSGP Collagen	  alpha-­‐1(XIII)	  chain 277 290 Q9R1N9 1214,59 47,91 0,006027174 1 1188,18 0,67 321,62 0,270682893 down-­‐regulated	  in	  ob/ob
9735 GPPGEpGEpGGSGP Collagen	  alpha-­‐1(I)	  chain 192 205 P11087 1222,58 48,01 0,012479191 1 905,24 0,89 242,5 0,26788476 down-­‐regulated	  in	  ob/ob
9877 PGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 812 824 P11087 1227,65 31,3 0,048052934 1 362,87 0,33 128,33 0,353652823 down-­‐regulated	  in	  ob/ob
10074 DpGKPGERGHpG Collagen	  alpha-­‐2(I)	  chain 509 520 Q01149 1234,64 25,97 0,036469953 1 558,83 0,78 276,39 0,494586905 down-­‐regulated	  in	  ob/ob
10156 GPpGEpGEpGGSGP Collagen	  alpha-­‐1(I)	  chain 192 205 P11087 1238,56 47,93 0,004385248 1 2233,37 0,78 809,17 0,362308977 down-­‐regulated	  in	  ob/ob
10290 VSINKELQNSI Kidney	  androgen-­‐regulated	  protein 25 35 P61110 1243,71 37,9 0,005541668 1 3103,25 0,11 232,88 0,075043906 down-­‐regulated	  in	  ob/ob
10361 KGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 815 827 P11087 1245,62 31,92 0,003485285 1 2947,74 1 1170,01 0,396917639 down-­‐regulated	  in	  ob/ob 0,01921313 1 1170,01 0 0 0 down-­‐regulated	  in	  ACEi
10497 DpGKpGERGHpG Collagen	  alpha-­‐2(I)	  chain 509 520 Q01149 1250,63 26,16 0,003485285 1 4719,03 0,89 1997,48 0,423281903 down-­‐regulated	  in	  ob/ob
10514 ApGEKGEGGPpGPA Collagen	  alpha-­‐1(III)	  chain 828 841 P08121 1251,61 38,23 0,039808966 0,89 1566,24 0,89 997,53 0,636894729 down-­‐regulated	  in	  ob/ob
10734 RpGEVGPpGPpGP Collagen	  alpha-­‐1(I)	  chain 907 919 P11087 1260,65 38,35 0,003485285 1 2843,92 1 5027,56 1,767827506 up-­‐regulated	  in	  ob/ob
10940 DGKTGPpGPAGQDG Collagen	  alpha-­‐1(I)	  chain 539 552 P11087 1268,62 40,04 0,013313568 1 439,65 0,44 99,96 0,227362675 down-­‐regulated	  in	  ob/ob
11018 GpPGPpGPpGPPSGG Collagen	  alpha-­‐1(I)	  chain 1170 1184 P11087 1271,62 47,98 0,003740306 1 687,19 0 0 0 down-­‐regulated	  in	  ob/ob
11248 EDVQETDTSQK Alpha-­‐1-­‐antitrypsin	  1-­‐1 25 35 P07758 1278,64 38,43 0,02548084 1 1580,89 0,89 488,09 0,308743809 down-­‐regulated	  in	  ACEi
12099 LGPYVAVFDRGD Napsin-A 373 384 O09043 1307,69 39,1 0,02206446 0 0 0,89 1521,42 1521,42 up-­‐regulated	  in	  ACEi
12726 GGpGERGEHGPpGP Collagen	  alpha-­‐1(III)	  chain 794 807 P08121 1331,65 30,51 0,014018563 0,78 795,79 0,89 2718,6 3,416227899 up-­‐regulated	  in	  ob/ob
12934 KLGVGSLQELAPQ Sperm	  flagellar	  protein	  1 119 131 Q99JL1 1338,8 39,93 0,007501881 0,78 1457,66 0 0 0 down-­‐regulated	  in	  ob/ob
13399 NGDDGEAGKpGRpG Collagen	  alpha-­‐1(I)	  chain 218 231 P11087 1357,65 31,57 0,012479191 1 4439,71 1 2522,84 0,568244322 down-­‐regulated	  in	  ob/ob
13533 SGNFIDQTRVLN Uromodulin 590 601 Q91X17 1362,72 38,83 0,006027174 1 2824,95 0,22 343,66 0,121651711 down-­‐regulated	  in	  ob/ob
13637 QTRVLNLGPITR Uromodulin 596 607 Q91X17 1366,85 33,58 0,02550148 0,78 387,01 0,22 36,75 0,094958787 down-­‐regulated	  in	  ob/ob
13692 GpPGEpGEpGGSGPM Collagen	  alpha-­‐1(I)	  chain 192 206 P11087 1369,62 48,02 0,00768409 0,89 445,2 0,33 28,86 0,064824798 down-­‐regulated	  in	  ob/ob
13864 WTDVGMSPRIES Pro-­‐epidermal	  growth	  factor 620 631 P01132 1376,73 37,67 0,012142689 0,78 114,1 0,11 6,53 0,0572305 down-­‐regulated	  in	  ob/ob
14045 PGAKGEPGDTGVKGD Collagen	  alpha-­‐1(I)	  chain 812 826 P11087 1383,69 32,05 0,007501881 0,78 86 0 0 0 down-­‐regulated	  in	  ob/ob
14400 INKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 27 38 P61110 1398,79 38,95 0,004385248 1 3872,94 0,11 252,71 0,065250172 down-­‐regulated	  in	  ob/ob
14644 QGELGEVGAQGpPGP Collagen	  alpha-­‐1(IX)	  chain 453 467 Q05722 1407,7 47,91 0,003740306 1 536,54 0 0 0 down-­‐regulated	  in	  ob/ob
14770 GQPGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 810 824 P11087 1412,74 31,8 0,005095706 1 1986,91 0,89 1144,64 0,576090512 down-­‐regulated	  in	  ob/ob
14987 GPpGPpGpAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 912 927 P11087 1421,72 39,36 0,005095706 1 7477,24 1 4524,82 0,605145749 down-­‐regulated	  in	  ob/ob
15063 GPpGPAGPAGPPGPIGN Collagen	  alpha-­‐1(I)	  chain 828 844 P11087 1424,7 48,22 0,027033297 0,89 5564,19 0,89 2188,46 0,393311515 down-­‐regulated	  in	  ob/ob
15130 GQpGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 810 824 P11087 1428,74 31,96 0,004385248 1 2860,63 1 1495,87 0,522916281 down-­‐regulated	  in	  ob/ob
15221 GEVGPpGPpGPAGEKG Collagen	  alpha-­‐1(I)	  chain 909 924 P11087 1433,72 38,81 0,01921313 1 3377,27 0,11 22,88 0,006774703 down-­‐regulated	  in	  ACEi
15293 GpPGPTGPTGPpGFpG Collagen	  alpha-­‐1(I)	  chain 321 336 P11087 1436,7 48,08 0,004385248 1 1797,88 0,56 200,6 0,111575856 down-­‐regulated	  in	  ob/ob
15342 SpGKAGEDGHPGkpG Collagen	  alpha-­‐2(I)	  chain 143 157 Q01149 1437,72 26,48 0,004385248 1 1795,05 0,89 702,97 0,391615832 down-­‐regulated	  in	  ob/ob
15427 GPpGPAGPAGPpGPIGN Collagen	  alpha-­‐1(I)	  chain 828 844 P11087 1440,7 48,22 0,016072859 0,89 1120,36 0,56 318,47 0,284256846 down-­‐regulated	  in	  ob/ob
15429 FLEQIHVLENSL Major	  urinary	  protein	  1 59 70 P11588 1440,7 38,72 0,03124018 0,89 498,55 0,22 38,2 0,076622204 down-­‐regulated	  in	  ACEi
15539 GPpGERGGpGPAGPRG Collagen	  alpha-­‐1(III)	  chain 503 518 P08121 1446,74 31,55 0,00705176 0,89 111,77 0,11 7,86 0,070322985 down-­‐regulated	  in	  ob/ob
15855 GRpGPpGPSGPRGQp Collagen	  alpha-­‐1(III)	  chain 560 574 P08121 1460,74 32,22 0,009919353 1 1037,2 0,22 174,22 0,167971462 down-­‐regulated	  in	  ob/ob
16362 DQTRVLNLGPITR Uromodulin 595 607 Q91X17 1481,88 33,69 0,004385248 1 6703,59 0,67 544,39 0,081208725 down-­‐regulated	  in	  ob/ob
16415 KNGDDGEAGKpGRpG Collagen	  alpha-­‐1(I)	  chain 217 231 P11087 1485,73 27,52 0,004385248 1 3759,82 1 1554,16 0,413360214 down-­‐regulated	  in	  ob/ob
16425 SINKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 26 38 P61110 1485,84 39,49 0,004344693 1 18784,43 0,11 8,15 0,00043387 down-­‐regulated	  in	  ob/ob
16583 GSpGSPGPDGKTGPpGP Collagen	  alpha-­‐1(I)	  chain 531 547 P11087 1492,74 39,9 0,016072859 1 4432,49 1 6727,79 1,517835348 up-­‐regulated	  in	  ob/ob
16733 GPpGPpGPpGpPGVSGGG Collagen	  alpha-­‐2(I)	  chain 1096 1113 Q01149 1500,73 48,28 0,012142689 0,89 2054,34 0,44 383,86 0,186853199 down-­‐regulated	  in	  ob/ob
16741 AHLINEKDGETFQ Major	  urinary	  protein	  1 121 133 P11588 1500,77 32,08 0,019906338 1 797,99 1 1488,35 1,865123623 up-­‐regulated	  in	  ob/ob
16857 KpGEQGVPGDLGApGP Collagen	  alpha-­‐1(I)	  chain 646 661 P11087 1506,78 40,49 0,039110041 1 2170,84 1 4362,62 2,009646036 up-­‐regulated	  in	  ob/ob
17232 KpGEQGVpGDLGApGP Collagen	  alpha-­‐1(I)	  chain 646 661 P11087 1522,78 40,4 0,007501881 1 2366,4 1 4196,38 1,77331812 up-­‐regulated	  in	  ob/ob
17342 DGQPGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 809 824 P11087 1527,78 33,82 0,010033808 1 1016,73 0,89 590,94 0,581216252 down-­‐regulated	  in	  ob/ob
17585 GPpGPpGppGLGGNFAS Collagen	  alpha-­‐1(I)	  chain 135 151 P11087 1538,73 48,37 0,013313568 0,89 6546,4 0,56 1514,25 0,231310339 down-­‐regulated	  in	  ob/ob
18066 SpGSPGPDGKTGPPGpAG Collagen	  alpha-­‐1(I)	  chain 532 549 P11087 1563,79 40,57 0,012479191 1 911,52 1 2220,7 2,436260312 up-­‐regulated	  in	  ob/ob
18443 ILGGQEAAAHARPYM Complement	  factor	  D 26 40 P03953 1583,81 33,09 0,017010274 0,78 3792,01 0,22 118,11 0,03114707 down-­‐regulated	  in	  ob/ob
18466 VSINKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 25 38 P61110 1584,92 40,18 0,005603303 0,89 20465,8 0,11 229,53 0,011215296 down-­‐regulated	  in	  ob/ob
Supplementary Table 1: List of urinary peptides associated to i) T2D nephropathy  and ii) treatment with RASi 
(enalapril) in the BTBRob/ob mouse model. 
19285 EVGPpGPpGPAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 910 927 P11087 1633,82 41,12 0,003740306 1 8059,6 1 3507,43 0,43518661 down-­‐regulated	  in	  ob/ob
19345 GSpGSpGPDGKTGPpGPAG Collagen	  alpha-­‐1(I)	  chain 531 549 P11087 1636,83 40,73 0,012479191 1 4111,71 0,89 6559,88 1,595414073 up-­‐regulated	  in	  ob/ob
19367 APEPYKRWYDVQS Complement	  factor	  D 88 100 P03953 1637,8 32,93 0,005603303 0,89 694,47 0,11 8,19 0,011793166 down-­‐regulated	  in	  ob/ob
19606 EVGPpGPpGpAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 910 927 P11087 1649,81 41,29 0,012479191 1 16535 1 9453,33 0,571716359 down-­‐regulated	  in	  ob/ob
19814 GLpGPAGPpGEAGKpGEQ Collagen	  alpha-­‐1(I)	  chain 633 650 P11087 1662,83 41 0,002949087 1 3541,81 1 6708,74 1,894155813 up-­‐regulated	  in	  ob/ob
20085 TGPIGPpGPAGApGDKGEA Collagen	  alpha-­‐1(I)	  chain 755 773 P11087 1676,84 41,36 0,004385248 1 1202,25 1 2971,04 2,471233105 up-­‐regulated	  in	  ob/ob
20385 GEVGPpGPpGPAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 909 927 P11087 1690,83 41,14 0,016072859 0,44 78,84 1 348,68 4,422628108 up-­‐regulated	  in	  ob/ob
20503 VSINKELQNSIIDLL Kidney	  androgen-­‐regulated	  protein 25 39 P61110 1697,99 40,83 0,003740306 1 26893,79 0 0 0 down-­‐regulated	  in	  ob/ob
20763 SPRIESASLQGSDRVL Pro-­‐epidermal	  growth	  factor 626 641 P01132 1713,91 34,12 0,012142689 0,78 4136,56 0,11 11,04 0,002668884 down-­‐regulated	  in	  ob/ob
21009 ASHEIATNLGDFALRL Alpha-­‐1-­‐antitrypsin	  1-­‐4 40 55 Q00897 1726,88 34,18 0,02550148 0,33 164,23 0,89 1183,23 7,204712903 up-­‐regulated	  in	  ob/ob
21108 PGQTGAAGTPGKMGPPGPPG EMI	  domain-­‐containing	  protein	  1 232 251 Q91VF5 1730,89 39,23 0,039110041 1 1534,05 0,89 939,39 0,612359441 down-­‐regulated	  in	  ob/ob
21455 pTGARGAPGDRGEAGPPGp Collagen	  alpha-­‐1(I)	  chain 781 799 P11087 1747,81 36,04 0,04691826 0,89 171,09 0,22 47,6 0,278216144 down-­‐regulated	  in	  ob/ob
21893 DGQPGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 809 827 P11087 1770,89 35,47 0,003485285 1 466,91 1 1073,81 2,299822236 up-­‐regulated	  in	  ob/ob
22065 YLNRDSEGSDGGELVLG Napsin-­‐A 215 231 O09043 1779,88 41,85 0,003740306 1 1575,48 1 2981,4 1,892375657 up-­‐regulated	  in	  ob/ob
22220 DGQpGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 809 827 P11087 1786,86 35,6 0,004385248 1 1371,97 1 2276 1,658928402 up-­‐regulated	  in	  ob/ob
22880 VGEKGPSGEpGTAGApGTAGP Collagen	  alpha-­‐2(I)	  chain 849 869 Q01149 1824,89 42,14 0,02550148 1 1030,46 1 2207,02 2,14178134 up-­‐regulated	  in	  ob/ob
22917 SPRIESASLQGSDRVLI Pro-­‐epidermal	  growth	  factor 626 642 P01132 1826,96 35,11 0,004385248 0,89 2980,38 0 0 0 down-­‐regulated	  in	  ob/ob
23042 GIpGTGGPpGENGKpGEpGP Collagen	  alpha-­‐1(III)	  chain 641 660 P08121 1834,89 41,58 0,012479191 1 3253,68 0,89 5840,31 1,794985985 up-­‐regulated	  in	  ob/ob
23356 IELSKASDYVDRNVEL ATP-­‐binding	  cassette	  sub-­‐family	  A	  member	  13 1292 1307 Q5SSE9 1849,93 34,64 0,012479191 1 965,05 0,89 5251,04 5,4412103 up-­‐regulated	  in	  ob/ob
23770 GPIGPpGPAGQpGDKGEGGSp Collagen	  alpha-­‐1(III)	  chain 764 784 P08121 1875,92 42,43 0,007164724 1 1160,08 0,67 297,86 0,256758155 down-­‐regulated	  in	  ob/ob
24239 ETGPAGRpGEVGPpGPpGPAG Collagen	  alpha-­‐1(I)	  chain 901 921 P11087 1900,94 42,53 0,003740306 1 1750,2 1 4283,88 2,447651697 up-­‐regulated	  in	  ob/ob
24713 ALDYDPVESKIYFAQTA Pro-­‐epidermal	  growth	  factor 522 538 P01132 1929,97 42,48 0,005603303 0,89 6125,23 0,11 18,25 0,00297948 down-­‐regulated	  in	  ob/ob
25110 VVPHPGSRPDSLEDDLIL Complement	  factor	  D 101 118 P03953 1958,05 35,31 0,004385248 1 25452,72 0,22 31,58 0,001240732 down-­‐regulated	  in	  ob/ob
25169 QGIpGTGGPpGENGKpGEpGP Collagen	  alpha-­‐1(III)	  chain 640 660 P08121 1962,95 42,24 0,019906338 1 2370,47 1 3687,96 1,555792733 up-­‐regulated	  in	  ob/ob
25395 RpGEVGPpGPpGpAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 907 927 P11087 1975,97 35,73 0,004385248 0,89 2080,23 0 0 0 down-­‐regulated	  in	  ob/ob
25689 GPKGSpGEAGRpGEAGLpGAKG Collagen	  alpha-­‐1(I)	  chain 507 528 P11087 1994,03 29,7 0,012479191 1 919,01 0,89 2294,12 2,496294926 up-­‐regulated	  in	  ob/ob
25768 SGNFIDQTRVLNLGPITR Uromodulin 590 607 Q91X17 2000,1 35,77 0,019906338 1 27322,53 0,56 2810,49 0,102863461 down-­‐regulated	  in	  ob/ob
26052 GRpGEVGPpGPpGPAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 906 927 P11087 2017,01 35,92 0,007501881 0,89 374,55 0,11 19,79 0,052836737 down-­‐regulated	  in	  ob/ob
26273 GRpGEVGPpGPpGpAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 906 927 P11087 2033,01 36,09 0,007501881 0,78 168,66 0 0 0 down-­‐regulated	  in	  ob/ob
26458 SVVPHPGSRPDSLEDDLIL Complement	  factor	  D 100 118 P03953 2045,07 35,9 0,031121543 0,78 1276,6 0,44 149,95 0,117460442 down-­‐regulated	  in	  ob/ob
26537 KNGETGPQGPpGPTGPAGDKGD Collagen	  alpha-­‐1(III)	  chain 609 630 P08121 2049,01 36,9 0,007164724 0,89 366,3 0,22 19,23 0,052497952 down-­‐regulated	  in	  ob/ob
27104 AGRpGEVGPpGPpGPAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 905 927 P11087 2088,05 36,3 0,012142689 0,89 348 0,44 59,64 0,17137931 down-­‐regulated	  in	  ob/ob
27322 AGRpGEVGPpGPpGpAGEKGSpG Collagen	  alpha-­‐1(I)	  chain 905 927 P11087 2104,02 36,19 0,014018563 1 481,07 0,67 125,88 0,261666701 down-­‐regulated	  in	  ob/ob
27962 GFpGPKGPSGDpGKpGERGHpG Collagen	  alpha-­‐2(I)	  chain 499 520 Q01149 2148,08 28,16 0,020886117 1 331,28 0,22 66,41 0,200464864 down-­‐regulated	  in	  ob/ob
28672 TTGEVGKpGERGLpGEFGLpGP Collagen	  alpha-­‐2(I)	  chain 569 590 Q01149 2199,05 34,97 0,02550148 1 1454,78 1 975,7 0,670685602 down-­‐regulated	  in	  ob/ob
30714 SGTTGEVGKpGERGLpGEFGLpGP Collagen	  alpha-­‐2(I)	  chain 567 590 Q01149 2343,17 37,04 0,039808966 0,89 2527,56 0,89 5404,25 2,138129263 up-­‐regulated	  in	  ob/ob
30739 PGSpGNVGPSGKEGpVGLpGIDGRP Collagen	  alpha-­‐2(I)	  chain 459 483 Q01149 2345,07 34,61 0,007501881 1 956,73 1 541,31 0,565791812 down-­‐regulated	  in	  ob/ob
32649 AVGGVQPPLDAMVEQGLLEKPVFS Napsin-­‐A 190 213 O09043 2480,32 45,06 0,007501881 0,78 505,29 0 0 0 down-­‐regulated	  in	  ob/ob
34635 AVGGVQPPLDAMVEQGLLEKPVFSF Napsin-­‐A 190 214 O09043 2627,39 45,64 0,012142689 0,78 17651,2 0,11 9,66 0,000547272 down-­‐regulated	  in	  ob/ob
34793 AVGGVQPPLDAmVEQGLLEKPVFSF Napsin-­‐A 190 214 O09043 2643,38 45,91 0,004385248 0,89 4457,79 0 0 0 down-­‐regulated	  in	  ob/ob
35125 REGSpGAEGSpGRDGApGAKGDRGETGP Collagen	  alpha-­‐1(I)	  chain 1003 1030 P11087 2669,26 29,68 0,048043989 1 3031,72 0,89 5197,89 1,714501999 up-­‐regulated	  in	  ob/ob
36104 KNGETGPQGPpGPTGPAGDKGDSGPpGPQG Collagen	  alpha-­‐1(III)	  chain 609 638 P08121 2742,29 39,65 0,031121543 1 3463,84 1 5616,43 1,621446141 up-­‐regulated	  in	  ob/ob
36597 GLpGPSGTTGEVGKpGERGLpGEFGLpGP Collagen	  alpha-­‐2(I)	  chain 562 590 Q01149 2780,39 38,92 0,048043989 0,89 664,51 0,89 1583,27 2,382612752 up-­‐regulated	  in	  ob/ob
41481 YLNRDSEGSDGGELVLGGSDPAHYVPPLTFIP Napsin-­‐A 215 246 O09043 3371,6 41,55 0,007501881 0,78 2389,84 0 0 0 down-­‐regulated	  in	  ob/ob
43263 SAPEPYKRWYDVQSVVPHPGSRPDSLEDDLIL Complement	  factor	  D 87 118 P03953 3664,78 33,12 0,007501881 0,78 8344,63 0 0 0 down-­‐regulated	  in	  ob/ob
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486 AVFEDHL Pro-­‐epidermal	  growth	  factor 697 703 P01132 829,44 36,03 0,014560573 1 249,38 0,82 146,97 0,589341567 down-­‐regulated	  in	  db/db
710 SpGRDGApG Collagen	  alpha-­‐1(I)	  chain 1012 1020 P11087 844,43 33,46 0,018081205 0 0 0,78 125,06 125,06 up	  regulated	  in	  ACEi
878 DPPKINDG Complement	  decay-­‐accelerating	  factor	  transmembrane	  isoform 232 239 Q61476 854,44 33,86 0,004667295 0,25 14,14 0,91 335,54 23,72984441 up-­‐regulated	  in	  db/db
931 ApGApGGKGD Collagen	  alpha-­‐1(III)	  chain 666 675 P08121 857,45 34,81 0,004667295 1 136,98 0,27 23,6 0,172287925 down-­‐regulated	  in	  db/db
1127 ApGERGPpG Collagen	  alpha-­‐1(III)	  chain 678 686 P08121 868,45 33,7 0,01324474 1 207,52 0,45 72,07 0,347291827 down-­‐regulated	  in	  db/db
1215 GEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 816 824 P11087 874,42 36,76 0,002348934 0,88 20,58 0 0 0 down-­‐regulated	  in	  db/db
1283 SmLKPSSL Pro-­‐epidermal	  growth	  factor 730 737 P01132 877,47 33,6 0,004667295 0,75 48,98 0 0 0 down-­‐regulated	  in	  db/db
1724 GPmGPRGpP Collagen	  alpha-­‐1(I)	  chain 204 212 P11087 896,48 34,05 0,005633844 0 0 0,82 148,88 148,88 up-­‐regulated	  in	  db/db
1760 GPpGEAGKpG Collagen	  alpha-­‐1(I)	  chain 639 648 P11087 897,47 33,68 0,005633844 1 176,22 0,09 28,52 0,161843151 down-­‐regulated	  in	  db/db
2081 IAVDPIER Pro-­‐epidermal	  growth	  factor 170 177 P01132 911,46 33,71 0,021057571 0,88 109,16 1 238,48 2,184683034 up-­‐regulated	  in	  db/db 0,018081205 1 238,48 0,67 62,94 0,263921503 down	  regulated	  in	  ACEi reversed	  by	  ACEi	  treatment
2465 QVSPGAKmP Transcription	  factor	  SOX-­‐6 378 386 P40645 929,47 35,74 0,006917625 0,36 54,13 1 1285,6 23,75023093 up	  regulated	  in	  ACEi
2988 pPGERGGpGP Collagen	  alpha-­‐1(III)	  chain 504 513 P08121 951,49 35,01 0,048419994 0,91 242,86 1 612,82 2,523346784 up	  regulated	  in	  ACEi
3062 GQpGEKGPpG Collagen	  alpha-­‐1(III)	  chain 926 935 P08121 954,47 34,61 0,008031871 0,88 115,09 0,18 14,54 0,126335911 down-­‐regulated	  in	  db/db
3144 GPpGESGREG Collagen	  alpha-­‐1(I)	  chain 996 1005 P11087 957,46 34,3 0,046851511 0,88 38,73 0,27 16,72 0,431706687 down-­‐regulated	  in	  db/db
3705 PGSPGEKGVPG Collagen	  alpha-­‐1(IV)	  chain 1019 1029 P02463 980,51 36,61 0,036037801 1 324,84 0,82 171,72 0,528629479 down-­‐regulated	  in	  db/db
4209 GEpGPAGSKGE Collagen	  alpha-­‐2(I)	  chain 352 362 Q01149 1000,5 36,97 0,046851511 0,88 99,4 0,27 30,68 0,308651911 down-­‐regulated	  in	  db/db
4497 SpGQRGEpGP Collagen	  alpha-­‐1(III)	  chain 363 372 P08121 1012,5 35,68 0,019594272 1 108,12 0,45 39,97 0,369681835 down-­‐regulated	  in	  db/db 0,006917625 0,45 39,97 1 980,33 24,52664498 up	  regulated	  in	  ACEi reversed	  by	  ACEi	  treatment
4520 ASLQPETLR Serine	  protease	  inhibitor	  A3K 288 296 P07759 1013,55 38,53 0,004667295 0,75 399,24 0 0 0 down-­‐regulated	  in	  db/db
4882 GQPGAKGEpGD Collagen	  alpha-­‐1(I)	  chain 810 820 P11087 1027,51 36,35 0,006274818 1 335,27 1 716,71 2,137709905 up-­‐regulated	  in	  db/db
5070 PGpEGGKGPAGP Collagen	  alpha-­‐1(III)	  chain 700 711 P08121 1035,54 35,71 0,002921538 1 475,8 0,64 135,75 0,285308953 down-­‐regulated	  in	  db/db
5204 SpGPDGKTGPp Collagen	  alpha-­‐1(I)	  chain 535 545 P11087 1040,53 36,08 0,004786026 1 1023,77 1 500,55 0,488928177 down-­‐regulated	  in	  db/db
5677 ApGDRGEAGPp Collagen	  alpha-­‐1(I)	  chain 787 797 P11087 1054,52 36,74 0,010321988 1 527,03 0,82 235,82 0,447450809 down-­‐regulated	  in	  db/db 0,018081205 0,82 235,82 0 0 0 down	  regulated	  in	  ACEi
5763 PpGSAGSpGKDG Collagen	  alpha-­‐1(I)	  chain 1132 1143 P11087 1057,52 36,16 0,018081205 0,91 1368,75 0,22 28,52 0,02083653 down	  regulated	  in	  ACEi
5886 GPpGPTGPTGPp Collagen	  alpha-­‐1(I)	  chain 321 332 P11087 1062,53 47,72 0,010955367 1 234,98 0,45 58,18 0,24759554 down-­‐regulated	  in	  db/db
6095 EVLASGRAIR Apoptosis-­‐inducing	  factor	  3 572 581 Q3TY86 1070,6 28,8 0,006274818 1 208,44 0,91 529,87 2,542074458 up-­‐regulated	  in	  db/db
6403 VFDQLGSYR Kidney	  androgen-­‐regulated	  protein 42 50 P61110 1083,52 37,6 0,027189316 0,25 18,14 0,73 399,86 22,0429989 up-­‐regulated	  in	  db/db
6763 VGEpGPAGSKGE Collagen	  alpha-­‐2(I)	  chain 351 362 Q01149 1099,56 37,4 0,005633844 1 87 0,09 20,74 0,238390805 down-­‐regulated	  in	  db/db
6921 GPpGPpGPpGSSG Collagen	  alpha-­‐1(III)	  chain 176 188 P08121 1107,53 47,75 0,03034805 0,75 57,17 0,09 18,96 0,33164247 down-­‐regulated	  in	  db/db
6952 GPpGPAGApGDKG Collagen	  alpha-­‐1(I)	  chain 759 771 P11087 1108,61 38,1 0,003307534 1 659,67 0,27 62,47 0,094698865 down-­‐regulated	  in	  db/db
7020 DQTRVLNLGP Uromodulin 595 604 Q91X17 1111,62 36,1 0,012123266 0,63 172,85 1 652,15 3,772924501 up-­‐regulated	  in	  db/db
7050 YSLHPDPIAT Osteopontin 32 41 P10923 1112,63 39,74 0,002902818 1 2600,18 0,18 71,89 0,027648086 down-­‐regulated	  in	  db/db
7064 GpPGSpGSpGEQ Collagen	  alpha-­‐1(I)	  chain 1107 1118 P11087 1113,49 47,49 0,035804475 1 516,47 0,73 286,49 0,554707921 down-­‐regulated	  in	  db/db 0,030751954 0,73 286,49 0 0 0 down	  regulated	  in	  ACEi
7091 SpGEAGRpGEAG Collagen	  alpha-­‐1(I)	  chain 511 522 P11087 1115,53 36,49 0,018010925 0,18 19,83 0,89 1131,39 57,05446293 up	  regulated	  in	  ACEi
7194 GPpGPTGPTGPpG Collagen	  alpha-­‐1(I)	  chain 321 333 P11087 1119,54 47,64 0,002348934 1 1084,75 0,64 130,17 0,12 down-­‐regulated	  in	  db/db
7213 GpGERGEHGPp Collagen	  alpha-­‐1(III)	  chain 795 805 P08121 1120,55 28,62 0,006274818 1 759,67 1 480,48 0,632485158 down-­‐regulated	  in	  db/db 0,006917625 1 480,48 0 0 0 down	  regulated	  in	  ACEi
7366 FLEQIHVLE Major	  urinary	  protein	  1 59 67 P11588 1126,63 38,99 0,00842438 0,75 438,91 0,09 4,74 0,010799481 down-­‐regulated	  in	  db/db
7394 IDQTRVLNLG Uromodulin 594 603 Q91X17 1127,6 37,67 0,001509036 1 77,04 0 0 0 down-­‐regulated	  in	  db/db
7545 GpPGPpGSpGPpG Collagen	  alpha-­‐2(I)	  chain 60 72 Q01149 1133,52 47,71 0,002348934 0,88 279,77 0 0 0 down-­‐regulated	  in	  db/db
7629 GQpGPpGPpGTAG Collagen	  alpha-­‐1(III)	  chain 329 341 P08121 1136,51 47,74 0,012873829 0,88 510,34 0,36 86,37 0,169240114 down-­‐regulated	  in	  db/db
7687 NIAVDPIERL Pro-­‐epidermal	  growth	  factor 169 178 P01132 1138,68 39,09 0,004667295 0,75 283,41 0 0 0 down-­‐regulated	  in	  db/db
7785 EpGRDGTpGGpG Collagen	  alpha-­‐1(III)	  chain 522 533 P08121 1143,54 37,18 0,011462987 1 840,03 0,55 373,65 0,444805543 down-­‐regulated	  in	  db/db
7814 DGApGAKGDRGE Collagen	  alpha-­‐1(I)	  chain 1016 1027 P11087 1144,57 31,02 0,004466958 1 1192,56 1 777,11 0,651631784 down-­‐regulated	  in	  db/db
8188 NIGFpGpKGPSG Collagen	  alpha-­‐2(I)	  chain 497 508 Q01149 1158,55 38,76 0,033066705 1 410,57 0,45 132,46 0,322624644 down-­‐regulated	  in	  db/db
8447 KpGEQGVPGDLG Collagen	  alpha-­‐1(I)	  chain 646 657 P11087 1168,61 37,46 0,016775791 1 1006,91 1 1942,09 1,928762253 up-­‐regulated	  in	  db/db
8738 ApGEKGEGGPpGP Collagen	  alpha-­‐1(III)	  chain 828 840 P08121 1180,58 37,84 0,001509036 1 3489,85 1 1837,6 0,526555583 down-­‐regulated	  in	  db/db
8774 KpGEpGPKGEVG Collagen	  alpha-­‐1(III)	  chain 654 665 P08121 1182,63 29,56 0,00193307 1 1581,07 1 942,48 0,596102639 down-­‐regulated	  in	  db/db 0,006917625 1 942,48 0 0 0 down	  regulated	  in	  ACEi
8824 TRVSSYRMW Complement	  factor	  D 240 248 P03953 1184,61 29,34 0,024837209 0,82 706,18 0,11 16,58 0,023478433 down	  regulated	  in	  ACEi
9139 SpGQRGEpGPQG Collagen	  alpha-­‐1(III)	  chain 363 374 P08121 1197,58 37,06 0,001509036 1 2201,62 1 1200,39 0,54523033 down-­‐regulated	  in	  db/db
9197 GEpGRDGTpGGpG Collagen	  alpha-­‐1(III)	  chain 521 533 P08121 1200,57 37,45 0,021057571 1 1464,99 0,91 1056,65 0,721267722 down-­‐regulated	  in	  db/db
9234 KpGERGLPGEF Collagen	  alpha-­‐2(I)	  chain 575 585 Q01149 1201,64 29,65 0,001509036 1 4494,09 1 1424,54 0,316980746 down-­‐regulated	  in	  db/db
9385 ApGDRGEAGPpGP Collagen	  alpha-­‐1(I)	  chain 787 799 P11087 1208,6 38,36 0,002358894 0,75 7627,11 1 20826,57 2,730597828 up-­‐regulated	  in	  db/db
9523 GPpGESGREGSpG Collagen	  alpha-­‐1(I)	  chain 996 1008 P11087 1214,56 37,26 0,038867999 1 1454,77 1 2738,8 1,882634368 up-­‐regulated	  in	  db/db
10139 GPpGPTGPAGDKGD Collagen	  alpha-­‐1(III)	  chain 617 630 P08121 1237,61 38,32 0,041353671 1 1122,39 0,55 498,08 0,443767318 down-­‐regulated	  in	  db/db
10236 LNSVFDQLGSY Kidney	  androgen-­‐regulated	  protein 39 49 P61110 1241,63 47,95 0,002348934 0,88 551,44 0 0 0 down-­‐regulated	  in	  db/db
10290 VSINKELQNSI Kidney	  androgen-­‐regulated	  protein 25 35 P61110 1243,71 37,9 0,00842438 1 2770,56 0,82 570,25 0,205824815 down-­‐regulated	  in	  db/db
10361 KGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 815 827 P11087 1245,62 31,92 0,006917625 1 1281,27 0 0 0 down	  regulated	  in	  ACEi
10386 PLHGGDWAVAPQ Synaptotagmin-­‐15 87 98 Q8C6N3 1246,54 37,94 0,035804475 0,75 784,6 0,45 134,58 0,171526893 down-­‐regulated	  in	  db/db
10734 RpGEVGPpGPpGP Collagen	  alpha-­‐1(I)	  chain 907 919 P11087 1260,65 38,35 0,004466958 1 2514,8 1 4190,9 1,666494353 up-­‐regulated	  in	  db/db
10940 DGKTGPpGPAGQDG Collagen	  alpha-­‐1(I)	  chain 539 552 P11087 1268,62 40,04 0,00226331 1 201,44 0,18 16,45 0,081662033 down-­‐regulated	  in	  db/db
11018 GpPGPpGPpGPPSGG Collagen	  alpha-­‐1(I)	  chain 1170 1184 P11087 1271,62 47,98 0,004466958 0,88 92,16 0,09 4,14 0,044921875 down-­‐regulated	  in	  db/db
11025 SPGpPGSPGPRGPP Collagen	  alpha-­‐1(XIV)	  chain 1729 1742 Q80X19 1271,66 38 0,004786026 1 2288,99 1 4753,22 2,076557783 up-­‐regulated	  in	  db/db
11248 EDVQETDTSQK Alpha-­‐1-­‐antitrypsin	  1-­‐1 25 35 P07758 1278,64 38,43 0,002348934 1 1068,41 1 2219,29 2,077189468 up-­‐regulated	  in	  db/db
11326 SpGSPGPDGKTGPp Collagen	  alpha-­‐1(I)	  chain 532 545 P11087 1281,66 38,78 0,005633844 1 97,53 0,09 32,65 0,334768789 down-­‐regulated	  in	  db/db
11438 NKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 28 38 P61110 1285,72 38,39 0,004667295 0,75 1445,81 0 0 0 down-­‐regulated	  in	  db/db
11688 GLpGERGRPGppG Collagen	  alpha-­‐1(I)	  chain 294 306 P11087 1293,69 29,92 0,002348934 1 793,12 1 1811,93 2,284559714 up-­‐regulated	  in	  db/db
11797 LILPDQGRMQQ Serine	  protease	  inhibitor	  A3K 275 285 P07759 1297,64 38,4 0,002348934 1 955,25 0,27 157,84 0,165234232 down-­‐regulated	  in	  db/db
11919 RLITEGVDTLEG Pro-­‐epidermal	  growth	  factor 554 565 P01132 1301,64 38,91 0,004667295 1 245,49 0,45 48,28 0,196667889 down-­‐regulated	  in	  db/db
11936 GAKGEpGDTGVKGD Collagen	  alpha-­‐1(I)	  chain 813 826 P11087 1302,66 31,79 0,006927736 1 211,4 0,36 55,56 0,2628193 down-­‐regulated	  in	  db/db
12096 GDpGKpGERGHpG Collagen	  alpha-­‐2(I)	  chain 508 520 Q01149 1307,65 25,46 0,01324474 1 1754,53 1 3035,54 1,730115757 up-­‐regulated	  in	  db/db
12099 LGPYVAVFDRGD Napsin-­‐A 373 384 O09043 1307,69 39,1 0,006917625 0 0 1 1405,12 1405,12 up	  regulated	  in	  ACEi
12174 QILSLTGDRVPL Nucleoporin	  Nup43 209 220 P59235 1310,79 40,19 0,001509036 1 319,48 0 0 0 down-­‐regulated	  in	  db/db
12270 IGFpGPKGPSGDpG Collagen	  alpha-­‐2(I)	  chain 498 511 Q01149 1313,67 39,06 0,022429314 1 173,76 0,36 54,44 0,313305709 down-­‐regulated	  in	  db/db
12325 GSRPDSLEDDLI Complement	  factor	  D 106 117 P03953 1315,64 38,84 0,027878213 0,88 688,46 0,91 1573,78 2,285942538 up-­‐regulated	  in	  db/db
12554 GPpGPTGPAGDKGDS Collagen	  alpha-­‐1(III)	  chain 617 631 P08121 1324,64 38,85 0,030021618 0,75 59,47 0,82 284,97 4,791827812 up-­‐regulated	  in	  db/db 0,024837209 0,82 284,97 0,11 19,58 0,068708987 down	  regulated	  in	  ACEi reversed	  by	  ACEi	  treatment
12605 GPpGPAGPAGPpGPIG Collagen	  alpha-­‐1(I)	  chain 828 843 P11087 1326,69 48,06 0,01066665 0,88 2230,21 1 4029,04 1,806574269 up-­‐regulated	  in	  db/db
12624 FLEQIHVLENS Major	  urinary	  protein	  1 59 69 P11588 1327,66 38,59 0,00226331 1 910,73 0,18 60,84 0,066803553 down-­‐regulated	  in	  db/db
12726 GGpGERGEHGPpGP Collagen	  alpha-­‐1(III)	  chain 794 807 P08121 1331,65 30,51 0,046851511 1 988,2 0,91 1480,66 1,498340417 up-­‐regulated	  in	  db/db
12934 KLGVGSLQELAPQ Sperm	  flagellar	  protein	  1 119 131 Q99JL1 1338,8 39,93 0,002658092 1 5906,82 0,27 158,67 0,026862169 down-­‐regulated	  in	  db/db
12996 NGDDGEAGKPGRpG Collagen	  alpha-­‐1(I)	  chain 218 231 P11087 1341,65 31,48 0,002348934 1 954,61 1 2898,26 3,036067085 up-­‐regulated	  in	  db/db
Supplementary Table 2: List of urinary peptides associated to i) T2D nephropathy  and ii) treatment with RASi 
(enalapril) in the Unxdb/db mouse model. 
13399 NGDDGEAGKpGRpG Collagen	  alpha-­‐1(I)	  chain 218 231 P11087 1357,65 31,57 0,01066665 1 1564,23 1 3037,37 1,941766876 up-­‐regulated	  in	  db/db
13864 WTDVGMSPRIES Pro-­‐epidermal	  growth	  factor 620 631 P01132 1376,73 37,67 0,002921538 1 96,82 0,09 10,07 0,104007436 down-­‐regulated	  in	  db/db
14373 AGPpGPAGPAGPpGPIG Collagen	  alpha-­‐1(I)	  chain 827 843 P11087 1397,73 48,13 0,01066665 1 809,54 1 1768,29 2,184314549 up-­‐regulated	  in	  db/db
14420 PGAKGEpGDTGVKGD Collagen	  alpha-­‐1(I)	  chain 812 826 P11087 1399,71 33,42 0,00193307 1 3061,85 1 4985,28 1,628192106 up-­‐regulated	  in	  db/db
14770 GQPGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 810 824 P11087 1412,74 31,8 0,046851511 1 2239,14 1 1880,29 0,839737578 down-­‐regulated	  in	  db/db
14858 GpRGLpGPpGAPGpQ Collagen	  alpha-­‐1(I)	  chain 174 188 P11087 1417,73 39,72 0,046000405 0,75 400,45 0,55 128,67 0,321313522 down-­‐regulated	  in	  db/db
14924 GPpGPTGPTGPpGFPG Collagen	  alpha-­‐1(I)	  chain 321 336 P11087 1420,69 48,02 0,004667295 0,75 521,12 0 0 0 down-­‐regulated	  in	  db/db
15221 GEVGPpGPpGPAGEKG Collagen	  alpha-­‐1(I)	  chain 909 924 P11087 1433,72 38,81 0,035804475 0,75 702,07 0,91 1537,19 2,189511017 up-­‐regulated	  in	  db/db
15293 GpPGPTGPTGPpGFpG Collagen	  alpha-­‐1(I)	  chain 321 336 P11087 1436,7 48,08 0,001509036 1 3355,44 1 722 0,215172973 down-­‐regulated	  in	  db/db
15530 GRpGEVGPpGPpGPAG Collagen	  alpha-­‐1(I)	  chain 906 921 P11087 1445,74 39,5 0,006554586 0,5 672,46 1 2168,98 3,225440918 up-­‐regulated	  in	  db/db
16118 ESGSPGENGSpGPMGP Collagen	  alpha-­‐1(II)	  chain 310 325 P28481 1471,67 48,22 0,03034805 0,75 245,51 0,18 31,66 0,128956051 down-­‐regulated	  in	  db/db
16128 VSINKELQNSIID Kidney	  androgen-­‐regulated	  protein 25 37 P61110 1471,82 39,58 0,004309984 1 26067,23 0,55 675,95 0,025931025 down-­‐regulated	  in	  db/db
16332 GPpGEAGKpGEQGVpG Collagen	  alpha-­‐1(I)	  chain 639 654 P11087 1480,71 39,19 0,004487973 1 1216,77 0,73 590,98 0,485695735 down-­‐regulated	  in	  db/db
16425 SINKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 26 38 P61110 1485,84 39,49 0,002348934 1 5638,18 0,18 241,96 0,042914558 down-­‐regulated	  in	  db/db
16668 QQVEASLQPETLR Serine	  protease	  inhibitor	  A3K 284 296 P07759 1497,81 37,83 0,030028334 1 74,58 0,27 21,15 0,283588093 down-­‐regulated	  in	  db/db
16733 GPpGPpGPpGpPGVSGGG Collagen	  alpha-­‐2(I)	  chain 1096 1113 Q01149 1500,73 48,28 0,01066665 1 2831,95 1 1854,09 0,654704356 down-­‐regulated	  in	  db/db
16741 AHLINEKDGETFQ Major	  urinary	  protein	  1 121 133 P11588 1500,77 32,08 0,006274818 1 383,34 1 897,59 2,341498409 up-­‐regulated	  in	  db/db
17232 KpGEQGVpGDLGApGP Collagen	  alpha-­‐1(I)	  chain 646 661 P11087 1522,78 40,4 0,031508511 1 2912,19 0,91 3798,09 1,304204053 up-­‐regulated	  in	  db/db
17342 DGQPGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 809 824 P11087 1527,78 33,82 0,046851511 1 702,02 1 1094,05 1,558431384 up-­‐regulated	  in	  db/db
17350 ALAHFDGILGLGFPT Napsin-­‐A 174 188 O09043 1527,82 38,48 0,046851511 1 1590,89 0,91 394,29 0,247842403 down-­‐regulated	  in	  db/db
17924 RDGApGAKGDRGETGP Collagen	  alpha-­‐1(I)	  chain 1015 1030 P11087 1555,8 28,13 0,021057571 1 1009,83 1 2316,36 2,29381183 up-­‐regulated	  in	  db/db
18066 SpGSPGPDGKTGPPGpAG Collagen	  alpha-­‐1(I)	  chain 532 549 P11087 1563,79 40,57 0,002348934 0,13 4,18 1 1069,27 255,8062201 up-­‐regulated	  in	  db/db
18174 GQPGAKGEPGDTGVKGD Collagen	  alpha-­‐1(I)	  chain 810 826 P11087 1568,8 33,54 0,001509036 1 1062,57 1 2485,05 2,338716508 up-­‐regulated	  in	  db/db
18466 VSINKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 25 38 P61110 1584,92 40,18 0,00193307 1 66953,46 1 6520,21 0,097384213 down-­‐regulated	  in	  db/db
18821 GIpGEKGPpGERGGPGp Collagen	  alpha-­‐1(III)	  chain 497 513 P08121 1605,82 32,95 0,01066665 1 2130 1 3514,86 1,650169014 up-­‐regulated	  in	  db/db
18875 TGSpGSpGPDGKTGPpGP Collagen	  alpha-­‐1(I)	  chain 530 547 P11087 1609,79 40,88 0,003271116 1 2758,37 1 4373,74 1,585624844 up-­‐regulated	  in	  db/db
19279 GApGpSGFQGLPGPPGPp Collagen	  alpha-­‐1(II)	  chain 657 674 P28481 1633,72 48,23 0,001509036 1 331,23 0 0 0 down-­‐regulated	  in	  db/db
19345 GSpGSpGPDGKTGPpGPAG Collagen	  alpha-­‐1(I)	  chain 531 549 P11087 1636,83 40,73 0,006274818 1 3894,08 1 5988,93 1,537957618 up-­‐regulated	  in	  db/db
19556 ATLNKTGKAVSYLGPK Copper	  transport	  protein	  ATOX1 53 68 O08997 1646,9 28,02 0,001509036 1 154,05 0 0 0 down-­‐regulated	  in	  db/db
19559 GQAGPpGppGLpGRTGAP Collagen	  alpha-­‐1(VII)	  chain 1267 1284 Q63870 1646,84 40,3 0,004487973 1 8357,77 0,73 825,11 0,098723703 down-­‐regulated	  in	  db/db
19701 SGVGGmGGYPGPAGpPGPp Collagen	  alpha-­‐1(III)	  chain 163 181 P08121 1655,75 48,34 0,004973959 1 1191,2 0,45 188,59 0,158319342 down-­‐regulated	  in	  db/db
19814 GLpGPAGPpGEAGKpGEQ Collagen	  alpha-­‐1(I)	  chain 633 650 P11087 1662,83 41 0,031508511 1 4052,25 1 5189,94 1,280755136 up-­‐regulated	  in	  db/db
19837 GpPGPTGPTGpPGFpGAVG Collagen	  alpha-­‐1(I)	  chain 321 339 P11087 1663,79 48,38 0,002962923 1 769,6 0,36 118,25 0,153651247 down-­‐regulated	  in	  db/db
19995 DpGFVGpEGLAGEpGpp Collagen	  alpha-­‐1(XVI)	  chain 436 452 Q8BLX7 1671,65 48,03 0,004487973 0,75 1030,59 1 2987,63 2,898951086 up-­‐regulated	  in	  db/db
20402 DGKTGPpGPAGQDGRPGp Collagen	  alpha-­‐1(I)	  chain 539 556 P11087 1691,85 35,18 0,001509036 1 340,67 1 1320,92 3,877418029 up-­‐regulated	  in	  db/db
20503 VSINKELQNSIIDLL Kidney	  androgen-­‐regulated	  protein 25 39 P61110 1697,99 40,83 0,003593092 1 19694,1 0,82 2691,01 0,136640415 down-­‐regulated	  in	  db/db
20534 DGQpGAKGEPGDTGVKGD Collagen	  alpha-­‐1(I)	  chain 809 826 P11087 1699,82 35,9 0,014560573 1 685,41 0,82 355,45 0,51859471 down-­‐regulated	  in	  db/db
20552 EDGKDGSpGEpGANGLpG Collagen	  alpha-­‐1(III)	  chain 462 479 P08121 1700,78 41,84 0,014560573 1 616,26 0,82 352,8 0,572485639 down-­‐regulated	  in	  db/db
20580 pGEPGQTGPAGPRGPAGSP Collagen	  alpha-­‐2(I)	  chain 126 144 Q01149 1701,86 38,55 0,002348934 1 283 0,27 29,17 0,103074205 down-­‐regulated	  in	  db/db
20728 GmPGSpGGpGNDGKpGpPG Collagen	  alpha-­‐1(III)	  chain 536 554 P08121 1711,79 40,67 0,030021618 0,5 976,2 1 3138,62 3,21514034 up-­‐regulated	  in	  db/db
20796 DGQpGAKGEpGDTGVKGD Collagen	  alpha-­‐1(I)	  chain 809 826 P11087 1715,82 35,95 0,014505996 1 921,43 0,73 436,77 0,474013219 down-­‐regulated	  in	  db/db 0,030751954 0,73 436,77 0 0 0 down	  regulated	  in	  ACEi
21257 TGSpGSpGPDGKTGpPGPAG Collagen	  alpha-­‐1(I)	  chain 530 549 P11087 1737,84 41,61 0,046851511 0,88 3616,54 0,91 5530,04 1,529096872 up-­‐regulated	  in	  db/db
21347 SGNFIDQTRVLNLGPI Uromodulin 590 605 Q91X17 1742,91 41,19 0,046851511 0,13 120,61 0,73 764,51 6,338694967 up-­‐regulated	  in	  db/db
21455 pTGARGAPGDRGEAGPPGp Collagen	  alpha-­‐1(I)	  chain 781 799 P11087 1747,81 36,04 0,031508511 0,88 76,87 0,18 27,91 0,363080526 down-­‐regulated	  in	  db/db
21480 KNGETGPQGPpGPTGPAGD Collagen	  alpha-­‐1(III)	  chain 609 627 P08121 1748,85 42,07 0,008235741 1 394,81 0,64 173,96 0,440617006 down-­‐regulated	  in	  db/db
21517 LSAPEPYKRWYDVQ Complement	  factor	  D 86 99 P03953 1750,85 33,74 0,03637941 0,91 893,67 0,56 268,98 0,300983585 down	  regulated	  in	  ACEi
21729 GpPGEPGPpGPPGpPGHLT Collagen	  alpha-­‐2(V)	  chain 1210 1228 Q3U962 1761,89 40,36 0,022100272 0,88 406,46 0,18 199,06 0,489740688 down-­‐regulated	  in	  db/db
21733 TTGEVGKpGERGLpGEF Collagen	  alpha-­‐2(I)	  chain 569 585 Q01149 1761,9 33,73 0,006274818 1 1026,22 0,91 1836,43 1,789509072 up-­‐regulated	  in	  db/db
21810 EDHLWVSDWAIPSVI Pro-­‐epidermal	  growth	  factor 700 714 P01132 1765,89 41,6 0,03034805 0,75 214,86 0,09 43,72 0,203481337 down-­‐regulated	  in	  db/db
21893 DGQPGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 809 827 P11087 1770,89 35,47 0,021057571 1 679,12 1 920,15 1,354915184 up-­‐regulated	  in	  db/db
22065 YLNRDSEGSDGGELVLG Napsin-­‐A 215 231 O09043 1779,88 41,85 0,001509036 1 490,82 1 1687,45 3,438022085 up-­‐regulated	  in	  db/db
22220 DGQpGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 809 827 P11087 1786,86 35,6 0,00193307 1 932 1 1636,7 1,75611588 up-­‐regulated	  in	  db/db
22305 IGAHGEDWDPAYVIHL Vacuolar	  protein	  sorting-­‐associated	  protein	  13C 2646 2661 Q8BX70 1791,9 35 0,00842438 0,75 231,9 0,09 10,08 0,043467012 down-­‐regulated	  in	  db/db
22694 SpGRDGApGAKGDRGETGP Collagen	  alpha-­‐1(I)	  chain 1012 1030 P11087 1812,91 29,3 0,043022835 1 203,26 0,82 419,34 2,063071928 up-­‐regulated	  in	  db/db
22729 pGpAGpKGETGEmGLSGLP Collagen	  alpha-­‐1(XXIII)	  chain 357 375 Q8K4G2 1814,9 41,54 0,021057571 1 1394,75 1 937,78 0,672364223 down-­‐regulated	  in	  db/db
22880 VGEKGPSGEpGTAGApGTAGP Collagen	  alpha-­‐2(I)	  chain 849 869 Q01149 1824,89 42,14 0,004786026 0,88 563,1 1 1687,86 2,997442728 up-­‐regulated	  in	  db/db
23042 GIpGTGGPpGENGKpGEpGP Collagen	  alpha-­‐1(III)	  chain 641 660 P08121 1834,89 41,58 0,001509036 1 2510,82 1 5195,54 2,069260242 up-­‐regulated	  in	  db/db
23356 IELSKASDYVDRNVEL ATP-­‐binding	  cassette	  sub-­‐family	  A	  member	  13 1292 1307 Q5SSE9 1849,93 34,64 0,002358894 0,75 442,18 1 3655,45 8,266882265 up-­‐regulated	  in	  db/db
23484 ADGQpGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 808 827 P11087 1857,92 35,06 0,038867999 1 291,29 0,91 671,06 2,303752274 up-­‐regulated	  in	  db/db
23764 SSLKHPSNIAVDPIERL Pro-­‐epidermal	  growth	  factor 162 178 P01132 1875,07 29,58 0,001509036 1 346,52 0 0 0 down-­‐regulated	  in	  db/db
23770 GPIGPpGPAGQpGDKGEGGSp Collagen	  alpha-­‐1(III)	  chain 764 784 P08121 1875,92 42,43 0,014505996 1 1102,74 0,73 600,28 0,544353157 down-­‐regulated	  in	  db/db
24239 ETGPAGRpGEVGPpGPpGPAG Collagen	  alpha-­‐1(I)	  chain 901 921 P11087 1900,94 42,53 0,01324474 0,88 876,13 1 2061,45 2,352904249 up-­‐regulated	  in	  db/db
24713 ALDYDPVESKIYFAQTA Pro-­‐epidermal	  growth	  factor 522 538 P01132 1929,97 42,48 0,002348934 0,88 910,69 0 0 0 down-­‐regulated	  in	  db/db
24883 EESSSMERNFNVEQISG Major	  urinary	  protein	  3 23 39 P04939 1941,95 42,94 0,002348934 1 320,25 0,18 16,14 0,050398126 down-­‐regulated	  in	  db/db
24907 RpGEVGPpGPpGPAGEKGSPG Collagen	  alpha-­‐1(I)	  chain 907 927 P11087 1943,98 35,51 0,038867999 1 1272,48 0,91 724,78 0,569580661 down-­‐regulated	  in	  db/db
25110 VVPHPGSRPDSLEDDLIL Complement	  factor	  D 101 118 P03953 1958,05 35,31 0,039008995 0,88 612,86 0,36 103,96 0,169630911 down-­‐regulated	  in	  db/db
25579 LSSLKHPSNIAVDPIERL Pro-­‐epidermal	  growth	  factor 161 178 P01132 1988,15 30,27 0,001509036 1 183,12 0 0 0 down-­‐regulated	  in	  db/db
25611 ApGApGPVGPAGKNGDRGETGP Collagen	  alpha-­‐1(I)	  chain 1039 1060 P11087 1990,01 35,87 0,031508511 1 1087,81 1 1877,48 1,725926403 up-­‐regulated	  in	  db/db
25859 SSLKHPSNIAVDPIERLM Pro-­‐epidermal	  growth	  factor 162 179 P01132 2006,1 30,24 0,004667295 0,75 156,44 0 0 0 down-­‐regulated	  in	  db/db
26103 EDHLWVSDWAIPSVIRV Pro-­‐epidermal	  growth	  factor 700 716 P01132 2021,01 35,74 0,004786026 1 677,13 1 1275,21 1,883257277 up-­‐regulated	  in	  db/db
26537 KNGETGPQGPpGPTGPAGDKGD Collagen	  alpha-­‐1(III)	  chain 609 630 P08121 2049,01 36,9 0,00226331 1 377,91 0,18 39,03 0,103278558 down-­‐regulated	  in	  db/db
26581 WTDQDSKDSTYSMSSTLT Ig	  kappa	  chain	  C	  region 55 72 P01837 2051,92 43,31 0,004667295 0,75 65,31 0 0 0 down-­‐regulated	  in	  db/db
27007 SQGKSISRIDPDGTNHQQL Pro-­‐epidermal	  growth	  factor 58 76 P01132 2080,08 30,51 0,001509036 1 719,5 0 0 0 down-­‐regulated	  in	  db/db
27161 GQpGAKGEpGDTGVKGDAGPpGP Collagen	  alpha-­‐1(I)	  chain 810 832 P11087 2093,01 36,72 0,031508511 1 730,82 1 1319,69 1,805766126 up-­‐regulated	  in	  db/db
27354 mSKNMLETSPQSLPQTPTT Forkhead	  box	  protein	  P2 430 448 P58463 2106,02 42,1 0,002348934 0,88 236,81 0 0 0 down-­‐regulated	  in	  db/db
27944 EEHTQSPIFVGKVVDPTHK Alpha-­‐1-­‐antitrypsin	  1-­‐4 395 413 Q00897 2147,13 28,35 0,007084217 0,88 406,7 0,09 46,41 0,114113597 down-­‐regulated	  in	  db/db
28103 NGIpGEKGPpGERGGpGPAGPRG Collagen	  alpha-­‐1(III)	  chain 496 518 P08121 2158,1 30,75 0,00193307 1 326,36 0,09 10,84 0,033214855 down-­‐regulated	  in	  db/db
28963 GPIGPpGPAGQpGDKGEGGSpGLpG Collagen	  alpha-­‐1(III)	  chain 764 788 P08121 2216,07 43,88 0,016775791 1 637,26 0,91 341,08 0,535228949 down-­‐regulated	  in	  db/db
29213 IASSNLLEPSGITIDYLTDTL Pro-­‐epidermal	  growth	  factor 642 662 P01132 2235,18 50,34 0,004667295 0,75 415,91 0 0 0 down-­‐regulated	  in	  db/db
30714 SGTTGEVGKpGERGLpGEFGLpGP Collagen	  alpha-­‐2(I)	  chain 567 590 Q01149 2343,17 37,04 0,025952657 1 1463,62 1 2096,59 1,43246881 up-­‐regulated	  in	  db/db
31518 WTDVGMSPRIESASLQGSDRVL Pro-­‐epidermal	  growth	  factor 620 641 P01132 2403,22 37,53 0,001509036 1 929,76 0 0 0 down-­‐regulated	  in	  db/db
32253 FQSPTYTQPHQGPSVMLSTEAF Uromodulin 464 485 Q91X17 2452,17 44,6 0,004667295 0,75 37,81 0 0 0 down-­‐regulated	  in	  db/db
34667 EEASSTGRNFNVEKINGEWHTII Major	  urinary	  protein	  1 19 41 P11588 2630,31 32,52 0,001509036 1 1368,32 0 0 0 down-­‐regulated	  in	  db/db
35125 REGSpGAEGSpGRDGApGAKGDRGETGP Collagen	  alpha-­‐1(I)	  chain 1003 1030 P11087 2669,26 29,68 0,009219572 0,88 684,2 0,91 2804,12 4,098392283 up-­‐regulated	  in	  db/db
40511 EDVQETDTSQKDQSPASHEIATNLGDFAIS Alpha-­‐1-­‐antitrypsin	  1-­‐1 25 54 P07758 3232,46 41,87 0,017898821 0,88 1264,04 0,18 222,84 0,176291889 down-­‐regulated	  in	  db/db
1502027 SNIAVDPIERL Pro-­‐epidermal	  growth	  factor 168 178 P01132 1225,72 39,95 0,002348934 1 3806,75 0,18 88,1 0,023143101 down-­‐regulated	  in	  db/db
1502180 LKWIERANMD Pro-­‐epidermal	  growth	  factor 539 548 P01132 1274,63 29,99 0,00193307 1 954,92 1 2645,97 2,77088133 up-­‐regulated	  in	  db/db
1504057 KNGDDGEAGKpGRpGERGPPGp Collagen	  alpha-­‐1(I)	  chain 217 238 P11087 2192,09 27,74 0,001509036 1 577,86 1 1322,75 2,289049251 up-­‐regulated	  in	  db/db 0,030751954 1 1322,75 0,89 788,79 0,596325836 down	  regulated	  in	  ACEi reversed	  by	  ACEi	  treatment
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db/db / db/m DIRECTION db/db / db/m
1127 ApGERGPpG Collagen	  alpha-­‐1(III)	  chain 0,004385248 0,067946968 down-­‐regulated	  in	  ob/ob 0,01324474 0,347291827 down-­‐regulated	  in	  db/db
3062 GQpGEKGPpG Collagen	  alpha-­‐1(III)	  chain 0,007164724 0,068955079 down-­‐regulated	  in	  ob/ob 0,00803187 0,126335911 down-­‐regulated	  in	  db/db
3144 GPpGESGREG Collagen	  alpha-­‐1(I)	  chain 0,003740306 0 down-­‐regulated	  in	  ob/ob 0,04685151 0,431706687 down-­‐regulated	  in	  db/db
4520 ASLQPETLR Serine	  protease	  inhibitor	  A3K 0,004385248 0 down-­‐regulated	  in	  ob/ob 0,0046673 0 down-­‐regulated	  in	  db/db
4882 GQPGAKGEpGD Collagen	  alpha-­‐1(I)	  chain 0,017010274 19,1167019 up-­‐regulated	  in	  ob/ob 0,00627482 2,137709905 up-­‐regulated	  in	  db/db
5204 SpGPDGKTGPp Collagen	  alpha-­‐1(I)	  chain 0,009919353 0,286652113 down-­‐regulated	  in	  ob/ob 0,00478603 0,488928177 down-­‐regulated	  in	  db/db
5677 ApGDRGEAGPp Collagen	  alpha-­‐1(I)	  chain 0,002949087 0,355568396 down-­‐regulated	  in	  ob/ob 0,01032199 0,447450809 down-­‐regulated	  in	  db/db
5886 GPpGPTGPTGPp Collagen	  alpha-­‐1(I)	  chain 0,005037542 0,068343455 down-­‐regulated	  in	  ob/ob 0,01095537 0,24759554 down-­‐regulated	  in	  db/db
7020 DQTRVLNLGP Uromodulin 0,00768409 6,595290932 up-­‐regulated	  in	  ob/ob 0,01212327 3,772924501 up-­‐regulated	  in	  db/db
7064 GpPGSpGSpGEQ Collagen	  alpha-­‐1(I)	  chain 0,004344693 0,015971149 down-­‐regulated	  in	  ob/ob 0,03580448 0,554707921 down-­‐regulated	  in	  db/db
7194 GPpGPTGPTGPpG Collagen	  alpha-­‐1(I)	  chain 0,014205913 0,116544308 down-­‐regulated	  in	  ob/ob 0,00234893 0,12 down-­‐regulated	  in	  db/db
7213 GpGERGEHGPp Collagen	  alpha-­‐1(III)	  chain 0,023549868 0,347919643 down-­‐regulated	  in	  ob/ob 0,00627482 0,632485158 down-­‐regulated	  in	  db/db
7366 FLEQIHVLE Major	  urinary	  protein	  1 0,004385248 0,045690793 down-­‐regulated	  in	  ob/ob 0,00842438 0,010799481 down-­‐regulated	  in	  db/db
7814 DGApGAKGDRGE Collagen	  alpha-­‐1(I)	  chain 0,031121543 0,653932776 down-­‐regulated	  in	  ob/ob 0,00446696 0,651631784 down-­‐regulated	  in	  db/db
8738 ApGEKGEGGPpGP Collagen	  alpha-­‐1(III)	  chain 0,012479191 0,493380476 down-­‐regulated	  in	  ob/ob 0,00150904 0,526555583 down-­‐regulated	  in	  db/db
9139 SpGQRGEpGPQG Collagen	  alpha-­‐1(III)	  chain 0,014018563 0,550282216 down-­‐regulated	  in	  ob/ob 0,00150904 0,54523033 down-­‐regulated	  in	  db/db
9523 GPpGESGREGSpG Collagen	  alpha-­‐1(I)	  chain 0,004385248 0,6529115 down-­‐regulated	  in	  ob/ob 0,038868 1,882634368 up-­‐regulated	  in	  db/db
10290 VSINKELQNSI Kidney	  androgen-­‐regulated	  protein 0,005541668 0,075043906 down-­‐regulated	  in	  ob/ob 0,00842438 0,205824815 down-­‐regulated	  in	  db/db
10734 RpGEVGPpGPpGP Collagen	  alpha-­‐1(I)	  chain 0,003485285 1,767827506 up-­‐regulated	  in	  ob/ob 0,00446696 1,666494353 up-­‐regulated	  in	  db/db
10940 DGKTGPpGPAGQDG Collagen	  alpha-­‐1(I)	  chain 0,013313568 0,227362675 down-­‐regulated	  in	  ob/ob 0,00226331 0,081662033 down-­‐regulated	  in	  db/db
11018 GpPGPpGPpGPPSGG Collagen	  alpha-­‐1(I)	  chain 0,003740306 0 down-­‐regulated	  in	  ob/ob 0,00446696 0,044921875 down-­‐regulated	  in	  db/db
12726 GGpGERGEHGPpGP Collagen	  alpha-­‐1(III)	  chain 0,014018563 3,416227899 up-­‐regulated	  in	  ob/ob 0,04685151 1,498340417 up-­‐regulated	  in	  db/db
12934 KLGVGSLQELAPQ Sperm	  flagellar	  protein	  1 0,007501881 0 down-­‐regulated	  in	  ob/ob 0,00265809 0,026862169 down-­‐regulated	  in	  db/db
13399 NGDDGEAGKpGRpG Collagen	  alpha-­‐1(I)	  chain 0,012479191 0,568244322 down-­‐regulated	  in	  ob/ob 0,01066665 1,941766876 up-­‐regulated	  in	  db/db
13864 WTDVGMSPRIES Pro-­‐epidermal	  growth	  factor 0,012142689 0,0572305 down-­‐regulated	  in	  ob/ob 0,00292154 0,104007436 down-­‐regulated	  in	  db/db
14770 GQPGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 0,005095706 0,576090512 down-­‐regulated	  in	  ob/ob 0,04685151 0,839737578 down-­‐regulated	  in	  db/db
15293 GpPGPTGPTGPpGFpG Collagen	  alpha-­‐1(I)	  chain 0,004385248 0,111575856 down-­‐regulated	  in	  ob/ob 0,00150904 0,215172973 down-­‐regulated	  in	  db/db
16425 SINKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 0,004344693 0,00043387 down-­‐regulated	  in	  ob/ob 0,00234893 0,042914558 down-­‐regulated	  in	  db/db
16733 GPpGPpGPpGpPGVSGGG Collagen	  alpha-­‐2(I)	  chain 0,012142689 0,186853199 down-­‐regulated	  in	  ob/ob 0,01066665 0,654704356 down-­‐regulated	  in	  db/db
16741 AHLINEKDGETFQ Major	  urinary	  protein	  1 0,019906338 1,865123623 up-­‐regulated	  in	  ob/ob 0,00627482 2,341498409 up-­‐regulated	  in	  db/db
17232 KpGEQGVpGDLGApGP Collagen	  alpha-­‐1(I)	  chain 0,007501881 1,77331812 up-­‐regulated	  in	  ob/ob 0,03150851 1,304204053 up-­‐regulated	  in	  db/db
17342 DGQPGAKGEpGDTGVK Collagen	  alpha-­‐1(I)	  chain 0,010033808 0,581216252 down-­‐regulated	  in	  ob/ob 0,04685151 1,558431384 up-­‐regulated	  in	  db/db
18066 SpGSPGPDGKTGPPGpAG Collagen	  alpha-­‐1(I)	  chain 0,012479191 2,436260312 up-­‐regulated	  in	  ob/ob 0,00234893 255,8062201 up-­‐regulated	  in	  db/db
18466 VSINKELQNSIIDL Kidney	  androgen-­‐regulated	  protein 0,005603303 0,011215296 down-­‐regulated	  in	  ob/ob 0,00193307 0,097384213 down-­‐regulated	  in	  db/db
Supplementary Table 3: Sequences of the 51 identical peptides 
in the two T2D nephropathy mouse strains. 
19345 GSpGSpGPDGKTGPpGPAG Collagen	  alpha-­‐1(I)	  chain 0,012479191 1,595414073 up-­‐regulated	  in	  ob/ob 0,00627482 1,537957618 up-­‐regulated	  in	  db/db
19814 GLpGPAGPpGEAGKpGEQ Collagen	  alpha-­‐1(I)	  chain 0,002949087 1,894155813 up-­‐regulated	  in	  ob/ob 0,03150851 1,280755136 up-­‐regulated	  in	  db/db
20503 VSINKELQNSIIDLL Kidney	  androgen-­‐regulated	  protein 0,003740306 0 down-­‐regulated	  in	  ob/ob 0,00359309 0,136640415 down-­‐regulated	  in	  db/db
21455 pTGARGAPGDRGEAGPPGp Collagen	  alpha-­‐1(I)	  chain 0,04691826 0,278216144 down-­‐regulated	  in	  ob/ob 0,03150851 0,363080526 down-­‐regulated	  in	  db/db
21893 DGQPGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 0,003485285 2,299822236 up-­‐regulated	  in	  ob/ob 0,02105757 1,354915184 up-­‐regulated	  in	  db/db
22065 YLNRDSEGSDGGELVLG Napsin-­‐A 0,003740306 1,892375657 up-­‐regulated	  in	  ob/ob 0,00150904 3,438022085 up-­‐regulated	  in	  db/db
22220 DGQpGAKGEpGDTGVKGDA Collagen	  alpha-­‐1(I)	  chain 0,004385248 1,658928402 up-­‐regulated	  in	  ob/ob 0,00193307 1,75611588 up-­‐regulated	  in	  db/db
22880 VGEKGPSGEpGTAGApGTAGP Collagen	  alpha-­‐2(I)	  chain 0,02550148 2,14178134 up-­‐regulated	  in	  ob/ob 0,00478603 2,997442728 up-­‐regulated	  in	  db/db
23042 GIpGTGGPpGENGKpGEpGP Collagen	  alpha-­‐1(III)	  chain 0,012479191 1,794985985 up-­‐regulated	  in	  ob/ob 0,00150904 2,069260242 up-­‐regulated	  in	  db/db
23356 IELSKASDYVDRNVEL ATP-­‐binding	  cassette	  sub-­‐family	  A	  member	  130,012479191 5,4412103 up-­‐regulated	  in	  ob/ob 0,00235889 8,266882265 up-­‐regulated	  in	  db/db
23770 GPIGPpGPAGQpGDKGEGGSp Collagen	  alpha-­‐1(III)	  chain 0,007164724 0,256758155 down-­‐regulated	  in	  ob/ob 0,014506 0,544353157 down-­‐regulated	  in	  db/db
24239 ETGPAGRpGEVGPpGPpGPAG Collagen	  alpha-­‐1(I)	  chain 0,003740306 2,447651697 up-­‐regulated	  in	  ob/ob 0,01324474 2,352904249 up-­‐regulated	  in	  db/db
24713 ALDYDPVESKIYFAQTA Pro-­‐epidermal	  growth	  factor 0,005603303 0,00297948 down-­‐regulated	  in	  ob/ob 0,00234893 0 down-­‐regulated	  in	  db/db
25110 VVPHPGSRPDSLEDDLIL Complement	  factor	  D 0,004385248 0,001240732 down-­‐regulated	  in	  ob/ob 0,039009 0,169630911 down-­‐regulated	  in	  db/db
26537 KNGETGPQGPpGPTGPAGDKGD Collagen	  alpha-­‐1(III)	  chain 0,007164724 0,052497952 down-­‐regulated	  in	  ob/ob 0,00226331 0,103278558 down-­‐regulated	  in	  db/db
30714 SGTTGEVGKpGERGLpGEFGLpGP Collagen	  alpha-­‐2(I)	  chain 0,039808966 2,138129263 up-­‐regulated	  in	  ob/ob 0,02595266 1,43246881 up-­‐regulated	  in	  db/db
35125 REGSpGAEGSpGRDGApGAKGDRGETGP Collagen	  alpha-­‐1(I)	  chain 0,048043989 1,714501999 up-­‐regulated	  in	  ob/ob 0,00921957 4,098392283 up-­‐regulated	  in	  db/db









2465 QVSPGAKmP Transcription factor SOX-6 378 386 P40645 0,025 130,23 0,007 23,75 Up
5677 ApGDRGEAGPp Collagen alpha-1(I) chain 787 797 P11087 0,038 0,05 0,018 Absent in UNxdb/db+RASi Down
10361 KGEpGDTGVKGDA Collagen alpha-1(I) chain 815 827 P11087 0,019 Absent in BTBRob/ob+RASi 0,007 Absent in UNxdb/db+RASi Down
12099 LGPYVAVFDRGD Napsin-A 373 384 O09043 0,022 1521,42 0,007 1405,12 Up
Supplementary Table 4: Overlap between peptides responding to RASi in 
two different T2D mouse strains. RASi treatment modified the abundance 
of 4 identical peptides (out of 11 and 18 peptides for the BTBRob/ob and 
UNxdb/db strains, respectively) that were all changed in the same 
direction in the two T2D strains. RASi, enalapril. 
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uniprot DIRECTION Mouse peptide
1127 ApGERGPpG Collagen alpha-1(III) chain 678 686 P08121 868,45 33,7 0,003 1 301,35 0,4 49,89 0,17 Down in Diab. 0,4 49,89 0,25 40,71 C	  Term 84440 KGDAGApGApGGKGDAGApGERGPpG Collagen	  alpha-­‐1	  (III)	  chain	   662 687 P02461 Down in patients Present in model
4497 SpGQRGEpGP Collagen alpha-1(III) chain 363 372 P08121 1012,5 35,68 0,02714521 1 1204,24 14,80 Up in Acei C	  Term 55523 SpGSNGApGQRGEpGPQG Collagen alpha-1 (III) chain 358 375 P02461 Down in patients Present in model
5599 ApGKDGPpGPAG Collagen alpha-1(III) chain 897 908 P08121 1051,54 36,38 0,04554068 0,38 255,56 0,19 Down in Acei C	  Term 76415 SNGNpGpPGPSGSPGKDGPpGpAG Collagen alpha-1 (III) chain 886 909 P02461 Down in patients Present in model
9139 SpGQRGEpGPQG Collagen alpha-1(III) chain 363 374 P08121 1197,58 37,06 0,015 0,9 1796,45 0,9 937,73 0,52 Down in Diab. 0,9 937,73 0,88 938,65 C	  Term 55523 SpGSNGApGQRGEpGPQG Collagen alpha-1 (III) chain 358 375 P02461 Down in patients Present in model
19345 GSpGSpGPDGKTGPpGPAG Collagen alpha-1(I) chain 531 549 P11087 1636,83 40,73 0,022 1 3801,59 0,9 6393,43 1,68 Up in Diab 0,9 6393,43 1 8346,86 C	  Term 48106 SpGSpGPDGKTGPPGpAG Collagen alpha-1 (I) chain 543 560 P02452 Up in patients Present in model
3062 GQpGEKGPpG Collagen alpha-1(III) chain 926 935 P08121 954,47 34,61 0,004 1 175,65 0,3 22,11 0,13 Down in Diab. 0,3 22,11 0,63 727,98 Cluster 133849 NTGApGSpGVSGPKGDAGQPGEkGSPGAQGPpGApGpLG Collagen alpha-1 (III) chain 910 948 P02461 Down in patients Present in model
8738 ApGEKGEGGPpGP Collagen alpha-1(III) chain 828 840 P08121 1180,58 37,84 0,014 1 2769,32 1 1321,03 0,48 Down in Diab. 1 1321,03 1 1059,1 Cluster 77184 NGEpGGKGERGApGEKGEGGPpG Collagen alpha-1 (III) chain 818 840 P02461 Down in patients Present in model
10361 KGEpGDTGVKGDA Collagen alpha-1(I) chain 815 827 P11087 1245,62 31,92 0,02666596 0 0 0,00 Down in Acei Cluster 97506 GPpGADGQpPGAKGEpGDAGAKGDAGpPGP Collagen alpha-1 (I) chain 815 843 P02452 Up in patients Present in model
10514 ApGEKGEGGPpGPA Collagen alpha-1(III) chain 828 841 P08121 1251,61 38,23 0,016 1 1661,82 0,7 808,67 0,49 Down in Diab. 0,7 808,67 0,75 626,12 Cluster 87460 GQNGEpGGKGERGApGEKGEGGPpG Collagen alpha-1 (III) chain 816 840 P02461 Down in patients Present in model
12554 GPpGPTGPAGDKGDS Collagen alpha-1(III) chain 617 631 P08121 1324,64 38,85 0,04554068 0,13 22,03 0,05 Down in Acei Cluster 32343 TGPGGDKGDTGPpGP Collagen	  alpha-­‐1	  (III)	  chain	   623 637 P02461 Up in patients Present in model
16857 KpGEQGVPGDLGApGP Collagen alpha-1(I) chain 646 661 P11087 1506,78 40,49 0,022 0,9 955,06 0,9 3264,15 3,42 Up in Diab 0,9 3264,15 0,88 3730,51 Cluster 58941 GPpGEAGKpGEQGVpGDLG Collagen alpha-1 (I) chain 650 668 P02452 Up in patients Present in model
19814 GLpGPAGPpGEAGKpGEQ Collagen alpha-1(I) chain 633 650 P11087 1662,83 41 0,012 1 3628,89 1 5518,2 1,52 Up in Diab 1 5518,2 0,88 4460,04 Cluster 58941 GPpGEAGKpGEQGVpGDLG Collagen alpha-1 (I) chain 650 668 P02452 Up in patients Present in model
21893 DGQPGAKGEpGDTGVKGDA Collagen alpha-1(I) chain 809 827 P11087 1770,89 35,47 0,005 1 534,46 1 994,8 1,86 Up in Diab 1 994,8 0,88 1037,79 Cluster 80891 ADGQPGAKGEpGDAGAKGDAGPPGp Collagen alpha-1 (I) chain 819 843 P02452 Up in patients Present in model
27104 AGRpGEVGPpGPpGPAGEKGSpG Collagen alpha-1(I) chain 905 927 P11087 2088,05 36,3 0,034 0,9 386,22 0,4 56,83 0,15 Down in Diab. 0,4 56,83 0,38 264,94 Cluster 108724 KEGGKGPRGETGPAGRpGEVGpPGPpGPAG Collagen alpha-1 (I) chain 903 932 P02452 Down in patients Present in model
710 SpGRDGApG Collagen alpha-1(I) chain 1012 1020 P11087 844,43 33,46 0,033 0,8  0,1 44,16 0,32 Down in Diab. 0,1 44,16 0,63 107,29 N	  Term 39163 SpGRDGSpGAKGDRG Collagen alpha-1 (I) chain 1023 1037 P02452 Down in patients Present in model
3438 DGKTGPpGPAG Collagen alpha-1(I) chain 539 549 P11087 968,51 37,23 0,035 0,8 302,22 0,3 51,98 0,17 Down in Diab. 0,3 51,98 0,38 45,93 N	  Term 5675 DGKTGPpGPA Collagen alpha-1 (I) chain 550 559 P02452 Down	  in	  patients Present in model
11018 GpPGPpGPpGPPSGG Collagen alpha-1(I) chain 1170 1184 P11087 1271,62 47,98 0,003 1 373,15 0 0 0,00 Down in Diab. 0 0 0 0 N	  Term 20756 GPpGpPGPPGPPS Collagen alpha-1 (I) chain 1181 1193 P02452 Down in patients Present in model
22220 DGQpGAKGEpGDTGVKGDA Collagen alpha-1(I) chain 809 827 P11087 1786,86 35,6 0,005 1 1101,23 1 1925,46 1,75 Up in Diab 1 1925,46 1 2200,93 N	  Term 77018 DGQPGAKGEpGDAGAKGDAGPPGp Collagen alpha-1 (I) chain 820 843 P02452 Up	  in	  patients Present in model
26537 KNGETGPQGPpGPTGPAGDKGD Collagen alpha-1(III) chain 609 630 P08121 2049,01 36,9 0,003 1 410,04 0,1 19,33 0,05 Down in Diab. 0,1 19,33 0,25 38,55 N	  Term 107460 KNGETGPQGPPGPTGPGGDKGDTGPpGpQG Collagen alpha-1 (III) chain 610 639 P02461 Down in patients Present in model
5677 ApGDRGEAGPp Collagen alpha-1(I) chain 787 797 P11087 1054,52 36,74 0,005 1 705,69 0,8 255,54 0,36 Down in Diab. 0,8 255,54 0,13 7,3 Same 17694 ApGDRGEpGpP Collagen alpha-1 (I) chain 798 808 P02452 Down in patients Present in model
23042 GIpGTGGPpGENGKpGEpGP Collagen alpha-1(III) chain 641 660 P08121 1834,89 41,58 0,003 1 2988,7 1 5594,12 1,87 Up in Diab 1 5594,12 1 7466,49 Same 61304 GLpGTGGPpGENGKPGEPGp Collagen alpha-1 (III) chain 642 661 P02461 Up in patients Present in model
21455 pTGARGAPGDRGEAGPPGp Collagen alpha-1(I) chain 781 799 P11087 1747,81 36,04 0,012 0,9 122,13 0,1 17,81 0,15 Down in Diab. 0,1 17,81 0 0 C	  Term 15593 GDRGEpGPpGP Collagen alpha-1 (I) chain 800 810 P02452 Down in patients
24239 ETGPAGRpGEVGPpGPpGPAG Collagen alpha-1(I) chain 901 921 P11087 1900,94 42,53 0,014 0,9 1210,1 1 3022,32 2,50 Up in Diab 1 3022,32 0,75 2705,68 C	  Term 108724 KEGGKGPRGETGPAGRpGEVGpPGPpGPAG Collagen alpha-1 (I) chain 903 932 P02452 Down in patients
35125 REGSpGAEGSpGRDGApGAKGDRGETGP Collagen alpha-1(I) chain 1003 1030 P11087 2669,26 29,68 0,050 0,9 1372,85 0,9 4247,82 3,09 Up in Diab 0,9 4247,82 0,75 3238,81 C	  Term 70674 EGSpGRDGSpGAKGDRGETGP Collagen alpha-1 (I) chain 1021 1041 P02452 Up in patients
1724 GPmGPRGpP Collagen alpha-1(I) chain 204 212 P11087 896,48 34,05 0,04554068 1 337,27 4,98 Up in Acei Cluster 14906 MGPRGPpGPpG Collagen alpha-1 (I) chain 217 227 P02452 Down	  in	  patients
1760 GPpGEAGKpG Collagen alpha-1(I) chain 639 648 P11087 897,47 33,68 0,005 0,8 152,95 0 0 0,00 Down in Diab. 0 0 0 0 Cluster 78332 AGPpGEAGkPGEQGVPGDLGAPGp Collagen alpha-1 (I) chain 646 669 P02452 Down	  in	  patients
4882 GQPGAKGEpGD Collagen alpha-1(I) chain 810 820 P11087 1027,51 36,35 0,04554068 1 1079,67 2,29 Up in Acei Cluster 101157 GPpGADGQpGAKGEpGDAGAKGDAGpPGPA	   Collagen alpha-1 (I) chain 815 844 P02452 Down	  in	  patients
5229 SpGAKGEVGPAG Collagen alpha-1(III) chain 345 356 P08121 1041,49 37,04 0,003 1 217,76 0,3 41,35 0,19 Down in Diab. 0,3 41,35 0 0 Cluster 132383 ARGNDGARGSDGQPGPpGppGTAGFpGSpGAKGEVGP Collagen alpha-1 (III) chain 319 355 P02461 Down in patients
7785 EpGRDGTpGGpG Collagen alpha-1(III) chain 522 533 P08121 1143,54 37,18 0,032 0,9 776,31 0,6 354,91 0,46 Down in Diab. 0,6 354,91 0,75 511,36 Cluster 124268 GEpGRDGVpGGpGMRGmpGSpGGpGSDGKpGPpG Collagen alpha-1 (III) chain 522 555 P02461 Down in patients
10734 RpGEVGPpGPpGP Collagen alpha-1(I) chain 907 919 P11087 1260,65 38,35 0,005 1 2489,18 1 4463,62 1,79 Up in Diab 1 4463,62 1 4614,38 Cluster 108724 KEGGKGPRGETGPAGRpGEVGpPGPpGPAG Collagen alpha-1 (I) chain 903 932 P02452 Down in patients
15427 GPpGPAGPAGPpGPIGN Collagen alpha-1(I) chain 828 844 P11087 1440,7 48,22 0,032 1 860,37 0,5 348,32 0,40 Down in Diab. 0,5 348,32 0,25 187,89 Cluster 121241 ADGQPGAkGEPGDAGAKGDAGPPGpAGPAGPPGPIG Collagen alpha-1 (I) chain 819 854 P02452 Down in patients
19701 SGVGGmGGYPGPAGpPGPp Collagen alpha-1(III) chain 163 181 P08121 1655,75 48,34 0,003 1 957,99 0,1 12,71 0,01 Down in Diab. 0,1 12,71 0 0 Cluster 19085 GpAGPpGPpGPpG Collagen	  alpha-­‐1	  (III)	  chain	   174 186 P02461 Down in patients
26052 GRpGEVGPpGPpGPAGEKGSpG Collagen alpha-1(I) chain 906 927 P11087 2017,01 35,92 0,005 1 330,9 0,1 29,98 0,09 Down in Diab. 0,1 29,98 0,13 10,29 Cluster 108724 KEGGKGPRGETGPAGRpGEVGpPGPpGPAG Collagen alpha-1 (I) chain 903 932 P02452 Down in patients
3144 GPpGESGREG Collagen alpha-1(I) chain 996 1005 P11087 957,46 34,3 0,005 0,9 61,28 0,1 4,94 0,08 Down in Diab. 0,1 4,94 0 0 N	  Term 127432 GPpGESGREGAPGAEGSpGRDGSpGAKGDRGETGp Collagen alpha-1 (I) chain 1007 1041 P02452 Down in patients
7020 DQTRVLNLGP Uromodulin 595 604 Q91X17 1111,62 36,1 0,004 0,7 172,48 1 1474,1 8,55 Up in Diab 1 1474,1 0,88 866,01 N	  Term 41513 DQSRVLNLGPITR Uromodulin 594 606 P07911 Up	  in	  patients
7213 GpGERGEHGPp Collagen alpha-1(III) chain 795 805 P08121 1120,55 28,62 0,011 1 675,01 0,5 213,06 0,32 Down in Diab. 0,5 213,06 0 0 N	  Term 28747 SpGERGETGPpGP Collagen alpha-1 (III) chain 796 808 P02461 Up in patients
10940 DGKTGPpGPAGQDG Collagen alpha-1(I) chain 539 552 P11087 1268,62 40,04 0,005 1 332,14 0,3 55,01 0,17 Down in Diab. 0,3 55,01 0 0 N	  Term 5675 DGKTGPpGPA Collagen alpha-1 (I) chain 550 559 P02452 Down	  in	  patients
17585 GPpGPpGppGLGGNFAS Collagen alpha-1(I) chain 135 151 P11087 1538,73 48,37 0,013 1 4789,87 0,5 1749,62 0,37 Down in Diab. 0,5 1749,62 0,63 1364,48 N	  Term 3508 GPpGPpGPpG Collagen alpha-1 (I) chain 145 154 P02452 Down in patients
5204 SpGPDGKTGPp Collagen alpha-1(I) chain 535 545 P11087 1040,53 36,08 0,004 1 1199,02 0,8 345,47 0,29 Down in Diab. 0,8 345,47 0,88 437,45 Same 14478 SpGPDGKTGPp Collagen alpha-1 (I) chain 546 556 P02452 Down	  in	  patients
18066 SpGSPGPDGKTGPPGpAG Collagen alpha-1(I) chain 532 549 P11087 1563,79 40,57 0,004 0,6 286,16 1 1548,7 5,41 Up in Diab 1 1548,7 0,88 1207,1 Same 48106 SpGSpGPDGKTGPPGpAG Collagen alpha-1 (I) chain 543 560 Up in patients
2465 QVSPGAKmP Transcription factor SOX-6 378 386 P40645 929,47 35,74 0,02590209 1 1342,35 1342,35 Up in Acei No	  ortholog
2806 YRELVHQ Alpha-1-antitrypsin 1-1 56 62 P07758 943,5 28,34 0,033 0,8 52,47 0,1 114,27 2,18 Up in Diab 0,1 114,27 0 0 No ortholog
4385 GPpGERGGpGP Collagen alpha-1(III) chain 503 513 P08121 1008,51 35,45 0,045 1 874,13 0,8 445,26 0,51 Down in Diab. 0,8 445,26 0,75 515,26 No	  ortholog
4520 ASLQPETLR Serine protease inhibitor A3K 288 296 P07759 1013,55 38,53 0,005 0,8 487,11 0 0 0,00 Down in Diab. 0 0 0 0 No	  ortholog
4801 IAVDPIERL Pro-epidermal growth factor 170 178 P01132 1024,52 36,98 0,005 1 421,76 0,5 80,37 0,19 Down in Diab. 0,5 80,37 0,5 88,3 No	  ortholog
5807 SpGGKGEMGPAG Collagen alpha-1(III) chain 390 401 P08121 1059,5 37,01 0,006 1 779,35 0,9 392,63 0,50 Down in Diab. 0,9 392,63 0,88 539,22 No	  ortholog
5886 GPpGPTGPTGPp Collagen alpha-1(I) chain 321 332 P11087 1062,53 47,72 0,003 1 370,72 0,4 20,43 0,06 Down in Diab. 0,4 20,43 0,13 23,88 No	  ortholog
6927 KPGppGEpGPQ Collagen alpha-1(VIII) chain 289 299 Q00780 1107,57 38,4 0,014 1 547,72 0,8 253,32 0,46 Down in Diab. 0,8 253,32 0,63 169,13 No	  ortholog
7050 YSLHPDPIAT Osteopontin 32 41 P10923 1112,63 39,74 0,005 0,9 1070,3 0,1 23,5 0,02 Down in Diab. 0,1 23,5 0,25 58,77 No ortholog
7064 GpPGSpGSpGEQ Collagen alpha-1(I) chain 1107 1118 P11087 1113,49 47,49 0,015 1 484,73 0,4 155,97 0,32 Down in Diab. 0,4 155,97 0,13 40,07 No	  ortholog
7194 GPpGPTGPTGPpG Collagen alpha-1(I) chain 321 333 P11087 1119,54 47,64 0,005 1 862,23 0,5 106,65 0,12 Down in Diab. 0,5 106,65 0,5 84,37 No	  ortholog
7366 FLEQIHVLE Major urinary protein 1 59 67 P11588 1126,63 38,99 0,007 0,8 545,85 0,1 5,21 0,01 Down in Diab. 0,1 5,21 0 0 No	  ortholog
7489 VSINKELQNS Kidney androgen-regulated protein 25 34 P61110 1130,63 36,82 0,020 0,9 1397,81 0,5 207,81 0,15 Down in Diab. 0,5 207,81 0,38 326,85 No ortholog
7719 GLpGAAGERGPSG Collagen alpha-1(III) chain 476 488 P08121 1140,56 38,23 0,006 1 376,95 0,7 133,98 0,36 Down in Diab. 0,7 133,98 0,63 182,67 No	  ortholog
7786 GPpGPLGpPGLPG Collagen alpha-1(XI) chain 1427 1439 Q61245 1143,56 47,71 0,012 1 4131,35 1 1743,9 0,42 Down in Diab. 1 1743,9 1 1505,82 No	  ortholog
8188 NIGFpGpKGPSG Collagen alpha-2(I) chain 497 508 Q01149 1158,55 38,76 0,032 1 323,7 0,5 94,3 0,29 Down in Diab. 0,5 94,3 0,5 61,69 No ortholog
10085 DpGGRLGpPGLpG Collagen alpha-1(XIX) chain 556 568 Q0VF58 1235,41 47,31 0,008 0,4 35,94 0,9 1025,82 28,54 Up in Diab 0,9 1025,82 1 1120,73 No	  ortholog
10290 VSINKELQNSI Kidney androgen-regulated protein 25 35 P61110 1243,71 37,9 0,006 1 2594,53 0,4 386,35 0,15 Down in Diab. 0,4 386,35 0,38 383,21 No	  ortholog
11919 RLITEGVDTLEG Pro-epidermal growth factor 554 565 P01132 1301,64 38,91 0,014 0,9 164,6 0,3 37,77 0,23 Down in Diab. 0,3 37,77 0 0 No ortholog
12099 LGPYVAVFDRGD Napsin-A 373 384 O09043 1307,69 39,1 0,02590209 1 1632,45 1632,45 Up in Acei No ortholog
12174 QILSLTGDRVPL Nucleoporin Nup43 209 220 P59235 1310,79 40,19 0,003 0,9 192,68 0 0 0,00 Down in Diab. 0 0 0 0 No ortholog
12934 KLGVGSLQELAPQ Sperm flagellar protein 1 119 131 Q99JL1 1338,8 39,93 0,004 0,9 2949,01 0,1 48,85 0,02 Down in Diab. 0,1 48,85 0,25 117,12 No ortholog
13700 QVEASLQPETLR Serine protease inhibitor A3K 285 296 P07759 1369,74 39,25 0,04496663 0,88 533,13 14,20 Up in Acei No ortholog
13864 WTDVGMSPRIES Pro-epidermal growth factor 620 631 P01132 1376,73 37,67 0,003 1 120,6 0 0 0,00 Down in Diab. 0 0 0,13 7,05 No ortholog
14400 INKELQNSIIDL Kidney androgen-regulated protein 27 38 P61110 1398,79 38,95 0,009 0,8 3425,5 0,1 227,44 0,07 Down in Diab. 0,1 227,44 0,25 195,99 No	  ortholog
15293 GpPGPTGPTGPpGFpG Collagen alpha-1(I) chain 321 336 P11087 1436,7 48,08 0,004 1 2355,02 0,8 415,14 0,18 Down in Diab. 0,8 415,14 0,38 243,16 No	  ortholog
15539 GPpGERGGpGPAGPRG Collagen alpha-1(III) chain 503 518 P08121 1446,74 31,55 0,032 0,8 124,11 0,2 27,96 0,23 Down in Diab. 0,2 27,96 0 0 No	  ortholog
15855 GRpGPpGPSGPRGQp Collagen alpha-1(III) chain 560 574 P08121 1460,74 32,22 0,018 0,8 530,74 0,2 61,16 0,12 Down in Diab. 0,2 61,16 0,25 528,92 No	  ortholog
16425 SINKELQNSIIDL Kidney androgen-regulated protein 26 38 P61110 1485,84 39,49 0,003 1 14665,03 0,1 185,59 0,01 Down in Diab. 0,1 185,59 0,13 501,58 No	  ortholog
16733 GPpGPpGPpGpPGVSGGG Collagen alpha-2(I) chain 1096 1113 Q01149 1500,73 48,28 0,016 1 2313,98 0,6 976,35 0,42 Down in Diab. 0,6 976,35 0,5 780,08 No	  ortholog
16741 AHLINEKDGETFQ Major urinary protein 1 121 133 P11588 1500,77 32,08 0,008 1 443,37 1 1086,99 2,45 Up in Diab 1 1086,99 0,88 1253,08 No	  ortholog
18466 VSINKELQNSIIDL Kidney androgen-regulated protein 25 38 P61110 1584,92 40,18 0,007 0,9 36532,78 0,5 2450,16 0,07 Down in Diab. 0,5 2450,16 0,5 4700,94 No	  ortholog
18821 GIpGEKGPpGERGGPGp Collagen alpha-1(III) chain 497 513 P08121 1605,82 32,95 0,040 1 2655,77 0,9 3850,57 1,45 Up in Diab 0,9 3850,57 0,88 4172,82 No ortholog
19279 GApGpSGFQGLPGPPGPp Collagen alpha-1(II) chain 657 674 P28481 1633,72 48,23 0,003 0,9 235,96 0 0 0,00 Down in Diab. 0 0 0 0 No ortholog
19367 APEPYKRWYDVQS Complement factor D 88 100 P03953 1637,8 32,93 0,005 0,8 459,85 0 0 0,00 Down in Diab. 0 0 0 0 No	  ortholog
19559 GQAGPpGppGLpGRTGAP Collagen alpha-1(VII) chain 1267 1284 Q63870 1646,84 40,3 0,008 0,9 5054,6 0,4 482,93 0,10 Down in Diab. 0,4 482,93 0,38 596,92 No ortholog
20503 VSINKELQNSIIDLL Kidney androgen-regulated protein 25 39 P61110 1697,99 40,83 0,004 1 30586,5 0,4 1040,98 0,03 Down in Diab. 0,4 1040,98 0,38 1367,12 No ortholog
20580 pGEPGQTGPAGPRGPAGSP Collagen alpha-2(I) chain 126 144 Q01149 1701,86 38,55 0,011 0,8 189,32 0,1 16,43 0,09 Down in Diab. 0,1 16,43 0,25 47,02 No ortholog
22065 YLNRDSEGSDGGELVLG Napsin-A 215 231 O09043 1779,88 41,85 0,003 1 923,54 1 2338,12 2,53 Up in Diab 1 2338,12 1 2588,15 No	  ortholog
23280 MSPRIESASLQGSDRVL Pro-epidermal growth factor 625 641 P01132 1844,98 34,5 0,006 0,9 2467,45 0,3 47,79 0,02 Down in Diab. 0,3 47,79 0,38 105,09 No ortholog
23356 IELSKASDYVDRNVEL ATP-binding cassette sub-family A member 13 1292 1307 Q5SSE9 1849,93 34,64 0,011 0,9 619,55 0,9 4548,52 7,34 Up in Diab 0,9 4548,52 0,88 4364,73 No	  ortholog
23764 SSLKHPSNIAVDPIERL Pro-epidermal growth factor 162 178 P01132 1875,07 29,58 0,003 0,9 386,07 0 0 0,00 Down in Diab. 0 0 0,13 391,8 No ortholog
23770 GPIGPpGPAGQpGDKGEGGSp Collagen alpha-1(III) chain 764 784 P08121 1875,92 42,43 0,014 1 1158,81 0,8 581,88 0,50 Down in Diab. 0,8 581,88 0,75 809,16 No	  ortholog
24713 ALDYDPVESKIYFAQTA Pro-epidermal growth factor 522 538 P01132 1929,97 42,48 0,003 0,9 4497,86 0 0 0,00 Down in Diab. 0 0 0 0 No	  ortholog
25110 VVPHPGSRPDSLEDDLIL Complement factor D 101 118 P03953 1958,05 35,31 0,004 1 16798,18 0,2 29,52 0,00 Down in Diab. 0,2 29,52 0,38 154,92 No	  ortholog
25579 LSSLKHPSNIAVDPIERL Pro-epidermal growth factor 161 178 P01132 1988,15 30,27 0,003 0,9 525,59 0 0 0,00 Down in Diab. 0 0 0 0 No ortholog
27962 GFpGPKGPSGDpGKpGERGHpG Collagen alpha-2(I) chain 499 520 Q01149 2148,08 28,16 0,034 0,9 311,04 0,4 80,38 0,26 Down in Diab. 0,4 80,38 0,25 37,21 No	  ortholog
28103 NGIpGEKGPpGERGGpGPAGPRG Collagen alpha-1(III) chain 496 518 P08121 2158,1 30,75 0,030 0,8 368,76 0,3 58,02 0,16 Down in Diab. 0,3 58,02 0,5 215,61 No ortholog
31518 WTDVGMSPRIESASLQGSDRVL Pro-epidermal growth factor 620 641 P01132 2403,22 37,53 0,003 0,9 1314,01 0 0 0,00 Down in Diab. 0 0 0 0 No ortholog
32253 FQSPTYTQPHQGPSVMLSTEAF Uromodulin 464 485 Q91X17 2452,17 44,6 0,025 0,9 267,68 0,2 40,28 0,15 Down in Diab. 0,2 40,28 0,63 3885,79 No ortholog
1502027 SNIAVDPIERL Pro-epidermal growth factor 168 178 P01132 1225,72 39,95 0,004 0,9 2002,59 0,1 23,2 0,01 Down in Diab. 0,1 23,2 0,13 25,56 No ortholog
1503005 ADNLELNAKGAILHA Meprin A subunit alpha 83 97 P28825 1548,8 32,63 0,040 1 696,44 0,9 1203,06 1,73 Up in Diab 0,9 1203,06 0,88 857,44 No ortholog
Supplementary Table 5: Similarity of urinary peptides associated to mouse and human T2D 





710 SpGRDGApG Collagen alpha-1(I) chain Down Down 39163
1127 ApGERGPpG Collagen alpha-1(III) chain Down Down 84440
3062 GQpGEKGPpG Collagen alpha-1(III) chain Down Down 133849
3438 DGKTGPpGPAG Collagen alpha-1(I) chain Down Down 5675
4497 SpGQRGEpGP Collagen alpha-1(III) chain Up Down 55523
5599 ApGKDGPpGPAG Collagen alpha-1(III) chain Down Down 76415
5677 ApGDRGEAGPp Collagen alpha-1(I) chain Down Down 17694
8738 ApGEKGEGGPpGP Collagen alpha-1(III) chain Down Down 77184
9139 SpGQRGEpGPQG Collagen alpha-1(III) chain Down Down 55523
10361 KGEpGDTGVKGDA Collagen alpha-1(I) chain Down Up 97506
10514 ApGEKGEGGPpGPA Collagen alpha-1(III) chain Down Down 87460
11018 GpPGPpGPpGPPSGG Collagen alpha-1(I) chain Down Down 20756
12554 GPpGPTGPAGDKGDS Collagen alpha-1(III) chain Down Up 32343
16857 KpGEQGVPGDLGApGP Collagen alpha-1(I) chain Up Up 58941
19345 GSpGSpGPDGKTGPpGPAG Collagen alpha-1(I) chain Up Up 48106
19814 GLpGPAGPpGEAGKpGEQ Collagen alpha-1(I) chain Up Up 58941
21893 DGQPGAKGEpGDTGVKGDA Collagen alpha-1(I) chain Up Up 80891
22220 DGQpGAKGEpGDTGVKGDA Collagen alpha-1(I) chain Up Up 77018
23042 GIpGTGGPpGENGKpGEpGP Collagen alpha-1(III) chain Up Up 61304
26537 KNGETGPQGPpGPTGPAGDKGD Collagen alpha-1(III) chain Down Down 107460






















Supplementary Table 6: The 21 differentially excreted peptides identified and used 
for the generation of the humanized classifier and their respective human ortholog 
identified in CKD273. Bold: orthology. RASi, enalapril. 
Peptide ID Sequence Protein name Regulation Diab/Non diab
Regulation 
Diab+RASi/Diab
Ortholog CKD273
